U.S. patent application number 12/258745 was filed with the patent office on 2009-06-18 for peptide-based passive immunization therapy for treatment of atherosclerosis.
Invention is credited to Jenny Bengtsson, Roland Carlsson, Jan Nilsson, Leif Strandberg.
Application Number | 20090155258 12/258745 |
Document ID | / |
Family ID | 28677712 |
Filed Date | 2009-06-18 |
United States Patent
Application |
20090155258 |
Kind Code |
A1 |
Nilsson; Jan ; et
al. |
June 18, 2009 |
PEPTIDE-BASED PASSIVE IMMUNIZATION THERAPY FOR TREATMENT OF
ATHEROSCLEROSIS
Abstract
The present invention relates to passive immunization for
treating or preventing atherosclerosis using an isolated human
antibody directed towards at least one oxidized fragment of
apolipoprotein B in the manufacture of a pharmaceutical composition
for therapeutical or prophylactical treatment of atherosclerosis by
means of passive immunization, as well as method for preparing such
antibodies, and a method for treating a mammal, preferably a human
using such an antibody to provide for passive immunization.
Inventors: |
Nilsson; Jan; (Genarp,
SE) ; Carlsson; Roland; (Lund, SE) ;
Bengtsson; Jenny; (Lund, SE) ; Strandberg; Leif;
(Kavlinge, SE) |
Correspondence
Address: |
GAUTHIER & CONNORS, LLP
225 FRANKLIN STREET, SUITE 2300
BOSTON
MA
02110
US
|
Family ID: |
28677712 |
Appl. No.: |
12/258745 |
Filed: |
October 27, 2008 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10679032 |
Oct 3, 2003 |
7468183 |
|
|
12258745 |
|
|
|
|
60421067 |
Oct 25, 2002 |
|
|
|
Current U.S.
Class: |
424/133.1 ;
435/69.6; 506/9; 530/387.3 |
Current CPC
Class: |
C07K 2317/622 20130101;
A61P 37/04 20180101; C07K 16/18 20130101; C07K 2317/21 20130101;
A61P 9/10 20180101; A61P 9/00 20180101; C07K 14/775 20130101; A61K
2039/505 20130101 |
Class at
Publication: |
424/133.1 ;
506/9; 435/69.6; 530/387.3 |
International
Class: |
A61K 39/395 20060101
A61K039/395; C40B 30/04 20060101 C40B030/04; C12P 21/02 20060101
C12P021/02; C07K 16/18 20060101 C07K016/18 |
Foreign Application Data
Date |
Code |
Application Number |
Oct 4, 2002 |
SE |
0202959-3 |
Aug 27, 2003 |
SE |
0302312-4 |
Claims
1. Use of at least one recombinant human antibody or antibody
fragment directed towards at least one oxidized fragment of
apolipoprotein B in the manufacture of a pharmaceutical composition
for therapeutical or prophylactical treatment of atherosclerosis by
means of passive immunization.
2. The use according to claim 1, wherein the oxidized fragment is
selected from one or more of the group consisting of (SEQ ID NO:
39) (SEQ ID NO: 40) (SEQ ID NO: 41) (SEQ ID NO: 42) (SEQ ID NO: 43)
(SEQ ID NO: 44) (SEQ ID NO: 45) (SEQ ID NO: 46) (SEQ ID NO: 47)
(SEQ ID NO: 48) (SEQ ID NO: 49) (SEQ ID NO: 50) (SEQ ID NO: 51)
(SEQ ID NO: 52) (SEQ ID NO: 53) (SEQ ID NO: 54) (SEQ ID NO: 55)
(SEQ ID NO: 56) (SEQ ID NO: 57) (SEQ ID NO: 58) (SEQ ID NO: 59)
(SEQ ID NO: 60) (SEQ ID NO: 61) (SEQ ID NO: 62) (SEQ ID NO: 63)
(SEQ ID NO: 64) (SEQ ID NO: 65) (SEQ ID NO: 66) (SEQ ID NO: 67)
(SEQ ID NO: 68) (SEQ ID NO: 69) (SEQ ID NO: 70) (SEQ ID NO: 71)
(SEQ ID NO: 72) (SEQ ID NO: 73) (SEQ ID NO: 74) (SEQ ID NO: 75), or
an active site thereof.
3. The use according to claim 1, wherein the fragment has been
oxidized using malone dealdehyde.
4. The use according to claim 1, wherein the fragment has been
oxidized using copper.
5. The use according to claim 1, wherein the antibody comprises the
variable heavy region (V.sub.H) selected from the group of nucleic
acid sequences consisting of: (SEQ. ID. NO. 1) (SEQ. ID. NO. 3)
(SEQ. ID. NO. 5) (SEQ. ID. NO. 7) (SEQ. ID. NO. 9) (SEQ. ID. NO.
11) (SEQ. ID. NO. 19) (SEQ. ID. NO. 21) (SEQ ID NO: 23) (SEQ. ID.
NO. 25) (SEQ. ID. NO. 27) (SEQ. ID. NO. 29) (SEQ. ID. NO. 31) (SEQ.
ID. NO. 33) (SEQ. ID. NO. 35) (SEQ. ID. NO. 37) in combination with
a variable light region (V.sub.L) selected from the group of
nucleic acid sequences consisting of: (SEQ. ID. NO. 2) (SEQ. ID.
NO. 4) (SEQ. ID. NO. 6) (SEQ. ID. NO. 8) (SEQ. ID. NO. 10) (SEQ.
ID. NO. 12) (SEQ. ID. NO. 20) (SEQ. ID. NO. 22) (SEQ. ID. NO. 24)
(SEQ. ID. NO. 26) (SEQ. ID. NO. 28) (SEQ. ID. NO. 30) (SEQ. ID. NO.
32) (SEQ. ID. NO. 34) (SEQ. ID. NO. 36) (SEQ. ID. NO. 38).
6. The use according to claim 5, wherein the antibody comprises the
variable heavy region (V.sub.H) (SEQ ID NO: 1) and the variable
light region (V.sub.L) (SEQ ID NO: 2).
7. The use according to claim 5, wherein the antibody comprises the
variable heavy region (V.sub.H) (SEQ ID NO: 3) and the variable
light region (V.sub.L). (SEQ ID NO: 4).
8. The use according to claim 5, wherein the antibody comprises the
variable heavy region (V.sub.H) (SEQ ID NO: 5) and the variable
light region (V.sub.L) (SEQ ID NO: 6).
9. The use according to claim 5, wherein the antibody comprises the
variable heavy region (V.sub.H) (SEQ ID NO: 7) and the variable
light region (V.sub.L) (SEQ ID NO: 8).
10. Use according to claim 5, wherein the antibody comprises the
variable heavy region (V.sub.H) (SEQ ID NO: 9) and the variable
light region (V.sub.L (SEQ ID NO: 10)
11. Use according to claims 5, wherein the antibody comprises the
variable heavy region (V.sub.H) (SEQ ID NO: 11) and the variable
light region (V.sub.L) (SEQ ID NO: 12)
12. Use according to claim 5, wherein the antibody comprises the
variable heavy region (V.sub.H) (SEQ ID NO: 19) and the variable
light region (V.sub.L) (SEQ ID NO: 20)
13. Use according to claim 5, wherein the antibody comprises the
variable heavy region (V.sub.H) (SEQ ID NO: 21) and the variable
light region (V.sub.L) (SEQ ID NO: 22)
14. Use according to claim 5, wherein the antibody comprises the
variable heavy region (V.sub.H) (SEQ ID NO: 23) and the variable
light region (V.sub.L) (SEQ ID NO: 24)
15. Use according to claim 5, wherein the antibody comprises the
variable heavy region (V.sub.H) (SEQ ID NO: 25) and the variable
light region (V.sub.L) (SEQ ID NO: 26)
16. Use according to claim 5, wherein the antibody comprises the
variable heavy region (V.sub.H) (SEQ ID NO: 27) and the variable
light region (V.sub.L) (SEQ ID NO: 28)
17. Use according to claims 5, wherein the antibody comprises the
variable heavy region (V.sub.H) (SEQ ID NO: 29) and the variable
light region (V.sub.L) (SEQ ID NO: 30)
18. Use according to claim 5, wherein the antibody comprises the
variable heavy region (V.sub.H) (SEQ ID NO: 31) and the variable
light region (V.sub.L) (SEQ ID NO: 32)
19. Use according to claim 5, wherein the antibody comprises the
variable heavy region (V.sub.H) (SEQ ID NO: 33) and the variable
light region (V.sub.L) (SEQ ID NO: 34)
20. Use according to claim 5, wherein the antibody comprises the
variable heavy region (V.sub.H) (SEQ ID NO: 35) and the variable
light region (V.sub.L) (SEQ ID NO: 36)
21. Use according to claim 5, wherein the antibody comprises the
variable heavy region (V.sub.H) (SEQ ID NO: 37) and the variable
light region (V.sub.L) (SEQ ID NO: 38)
22. Antibodies raised against fragments of apo B100 comprising a
variable heavy region (V.sub.H) selected from the group of nucleic
acid sequences consisting of (SEQ. ID. NO. 1) (SEQ. ID. NO. 3)
(SEQ. ID. NO. 5) (SEQ. ID. NO. 7) (SEQ. ID. NO. 9) (SEQ. ID. NO.
11) (SEQ. ID. NO. 19) (SEQ. ID. NO. 21) (SEQ. ID. NO. 23) (SEQ. ID.
NO. 25) (SEQ. ID. NO. 27) (SEQ. ID. NO. 29) (SEQ. ID. NO. 31) (SEQ.
ID. NO. 33) (SEQ. ID. NO. 35) (SEQ. ID. NO. 37) in combination with
a variable light region (V.sub.L) selected from the group of
nucleic acid sequences consisting of (SEQ. ID. NO. 2) (SEQ. ID. NO.
4) (SEQ. ID. NO. 6) (SEQ. ID. NO. 8) (SEQ. ID. NO. 10) (SEQ. ID.
NO. 12) (SEQ. ID. NO. 20) (SEQ. ID. NO. 22) (SEQ. ID. NO. 24) (SEQ.
ID. NO. 26) (SEQ. ID. NO. 28) (SEQ. ID. NO. 30) (SEQ. ID. NO. 32)
(SEQ. ID. NO. 34) (SEQ. ID. NO. 36) (SEQ. ID. NO. 38)
23. Antibody according to claim 22, wherein the antibody comprises
the variable heavy region (V.sub.H) (SEQ ID NO: 1) and the variable
light region (V.sub.L) (SEQ ID NO: 2)
24. Antibody according to claim 22, wherein the antibody comprises
the variable heavy region (V.sub.H) (SEQ ID NO: 3) and the variable
light region (V.sub.L) (SEQ ID NO: 4)
25. Antibody according to claim 22, wherein the antibody comprises
the variable heavy region (V.sub.H) (SEQ ID NO: 5) and the variable
light region (V.sub.L) (SEQ ID NO: 6)
26. Antibody according to claim 22, wherein the antibody comprises
the variable heavy region (V.sub.H) (SEQ ID NO: 7) and the variable
light region (V.sub.L) (SEQ ID NO: 8)
27. Antibody according to claim 22, wherein the antibody comprises
the variable heavy region (V.sub.H) (SEQ ID NO: 9) and the variable
light region (V.sub.L) (SEQ ID NO: 10)
28. Antibody according to claim 22 wherein the antibody comprises
the variable heavy region (V.sub.H) (SEQ ID NO: 11) and the
variable light region (V.sub.L) (SEQ ID NO: 12)
29. Method for preparation of a isolated antibody according to
claim 22, using a fragment library to generate specific human
antibody fragments against oxidized, in particular MDA modified
peptides derived from Apo B100, whereupon identified antibody
fragments having the desired characteristics are rebuilt into full
length human immunoglobulin to be used for therapeutic
purposes.
30. Method for amplification of a isolated human antibody according
to claim 22, using a recombinant technology, comprising transfer of
genes encoding the variable parts of selected scFv to full length
human IgG1 vestors using a PCR-amplification wherein primers used,
are: primers for amplification of VH-segments: TABLE-US-00007 5'VH:
(SEQ. ID. NO: 13) 5'-GGTGTGCATTCCGAGGTGCAGCTGTTGGAG 3'VH: (SEQ. ID.
NO: 14) 5'-GACGTACGACTCACCTGAGCTCACGGTGACCAG
and primers for amplification of VL-segments: TABLE-US-00008 5'VL:
(SEQ. ID. NO: 15) 5'-GGTGTGCATTCCCAGTCTGTGCTGACTCAG 3'VL: (SEQ. ID.
NO: 16) 5'-GACGTACGTTCTACTCACCTAGGACCGTCAGCTT
31. Method according to claim 30, wherein colonies containing heavy
chain regions and light chain region plasmids with variable heavy
region and variable light chain inserts were identified by colony
PCR using TABLE-US-00009 Forward primer: 5'-ATGGGTGACAATGACATC
(SEQ. ID. NO: 17) Reverse primer: 5'-AAGCTTGCTAGCGTACG (SEQ. ID.
NO: 18)
32. Method for passive immunization of mammals, preferably humans,
wherein a therapeutically or prophylactically effective amount of a
isolated human antibody directed towards at least one oxidized
fragment of apolipoprotein B is administered for treatment of
atherosclerosis.
33. Method according to claim 32, the oxidized fragment is selected
from one or more of the group consisting of (SEQ ID NO: 39) (SEQ ID
NO: 40) (SEQ ID NO: 41) (SEQ ID NO: 42) (SEQ ED NO: 43) (SEQ ID NO:
44) (SEQ ID NO: 45) (SEQ ID NO: 46) (SEQ ID NO: 47) (SEQ ID NO: 48)
(SEQ ID NO: 49) (SEQ ID NO: 50) (SEQ ID NO: 51) (SEQ ID NO: 52)
(SEQ ID NO: 53) (SEQ ID NO: 54) (SEQ ID NO: 55) (SEQ ID NO: 56)
(SEQ ID NO: 57) (SEQ ED NO: 58) (SEQ ID NO: 59) (SEQ ID NO: 60)
(SEQ ID NO: 61) (SEQ ID NO: 62) (SEQ ID NO: 63) (SEQ ID NO: 64)
(SEQ ID NO: 65) (SEQ ID NO: 66) (SEQ ID NO: 67) (SEQ ID NO: 68)
(SEQ ID NO: 69) (SEQ ID NO: 70) (SEQ ID NO: 71) (SEQ ID NO: 72)
(SEQ ID NO: 73) (SEQ ID NO: 74) (SEQ ID NO: 75), or an active site
thereof.
34. Method according to claim 3Z wherein the antibody comprises
antibodies raised against fragments of apo B100 comprising a
variable heavy region (V.sub.H) selected from the group of nucleic
acid sequences consisting of (SEQ. ID. NO. 1) (SEQ. ID. NO. 3)
(SEQ. ID. NO. 5) (SEQ. ID. NO. 7) (SEQ. ID. NO. 9) (SEQ. ID. NO.
11) (SEQ. ID. NO. 19) (SEQ. ID. NO. 21) (SEQ. ID. NO. 23) (SEQ. ID.
NO. 25) (SEQ. ID. NO. 27) (SEQ. ID. NO. 29) (SEQ. ID. NO. 31) (SEQ.
ID. NO. 33) (SEQ. ID. NO. 35) (SEQ. ID. NO. 37) in combination with
a variable light region (V.sub.L) selected from the group of
nucleic acid sequences consisting of (SEQ. ID. NO. 2) (SEQ. ID. NO.
4) (SEQ. ID. NO. 6) (SEQ. ID. NO. 8) (SEQ. ID. NO. 10) (SEQ. ID.
NO. 12) (SEQ. ID. NO. 20) (SEQ. ID. NO. 22) (SEQ. ID. NO. 24) (SEQ.
ID. NO. 26) (SEQ. ID. NO. 28) (SEQ. ID. NO. 30) (SEQ. ID. NO. 32)
(SEQ. ID. NO. 34) (SEQ. ID. NO. 36) (SEQ. ID. NO. 38)
35. Method according to claim 34, wherein the antibody comprises
the variable heavy region (V.sub.H) (SEQ ID NO: 1) and the variable
light region (V.sub.L) (SEQ ID NO: 2)
36. Method according to claim 34, wherein the antibody comprises
the variable heavy region (V.sub.H) (SEQ ID NO: 3) and the variable
light region (V.sub.L) (SEQ ID NO: 4)
37. Method according to claims 34, wherein the antibody comprises
the variable heavy region (V.sub.H) (SEQ ID NO: 5) and the variable
light region (V.sub.L) (SEQ ID NO: 6)
38. Method according to claim 34, wherein the antibody comprises
the variable heavy region (V.sub.H) (SEQ ID NO: 7) and the variable
light region (V.sub.L) (SEQ ID NO: 8)
39. Method according to claim 34, wherein the antibody comprises
the variable heavy region (V.sub.H) (SEQ ID NO: 9) and the variable
light region (V.sub.L) (SEQ ID NO: 10)
40. Method according to claim 34, wherein the antibody comprises
the variable heavy region (V.sub.H) (SEQ ID NO: 11) and the
variable light region (V.sub.L) (SEQ ID NO: 12)
41. Method according to claim 34, wherein the antibody comprises
the variable heavy region (V.sub.H) (SEQ ID NO: 19) and the
variable light region (V.sub.L) (SEQ ID NO: 20)
42. Method according to claim 34, wherein the antibody comprises
the variable heavy region (V.sub.H) (SEQ ID NO: 21) and the
variable light region (V.sub.L) (SEQ ID NO: 22)
43. Method according to claim 34, wherein the antibody comprises
the variable heavy region (V.sub.H) (SEQ ID NO: 23) and the
variable light region (V.sub.L) (SEQ ID NO: 24)
44. Method according to claim 34, wherein the antibody comprises
the variable heavy region (V.sub.H) (SEQ ID NO: 25) and the
variable light region (V.sub.L) (SEQ ID NO: 26)
45. Method according to claims 34, wherein the antibody comprises
the variable heavy region (V.sub.H) (SEQ ID NO: 27) and the
variable light region (V.sub.L) (SEQ ID NO: 28)
46. Method according to claim 34, wherein the antibody comprises
the variable heavy region (V.sub.H) (SEQ ID NO: 29) and the
variable light region (V.sub.L) (SEQ ID NO: 30)
47. Method according to claim 34, wherein the antibody comprises
the variable heavy region (V.sub.H) (SEQ ID NO: 31) and the
variable light region (V.sub.L) (SEQ ID NO: 32)
48. Method according to claim 34, wherein the antibody comprises
the variable heavy region (V.sub.H) (SEQ ID NO: 33) and the
variable light region (V.sub.L) (SEQ ID NO: 34)
49. Method according to claim 34, wherein the antibody comprises
the variable heavy region (V.sub.H) (SEQ ID NO: 35) and the
variable light region (V.sub.L) (SEQ ID NO: 36)
50. Method according to claim 34, wherein the antibody comprises
the variable heavy region (V.sub.H) (SEQ ID NO: 37) and the
variable light region (V.sub.L) (SEQ ID NO: 38)
51. A pharmaceutical composition comprising an isolated human
antibody directed towards at least one oxidized fragment of
apolipoprotein B for therapeutical or prophylactical treatment of
atherosclerosis by means of passive immunization, which antibody is
present in combination with a pharmaceutical excipient.
Description
PRIORITY INFORMATION
[0001] This application is a divisional of U.S. patent application
Ser. No. 10/679,032 filed on Oct. 3, 2003 which claims priority to
U.S. Provisional Patent Appln. No. 60/421,067, filed Oct. 25, 2002,
Swedish Patent Application No. 0302312-4, filed Aug. 27, 2003 and
Swedish Patent Application No. 0202959-3, filed Oct. 4, 2002 all of
which are incorporated herein in their entirety.
BACKGROUND OF THE INVENTION
[0002] 1. Field of Invention
[0003] The present invention relates to new recombinant human
antibodies raised against peptides being derivatives of
apolipoprotein B, in particular antibodies to be used for
immunization therapy for treatment of atherosclerosis, method for
their preparation, and method for passive immunization using said
antibodies.
In Particular the Invention Includes:
[0004] The use of any isolated recombinant antibody raised against
an oxidized form of the peptides listed in table 1, in particular
MDA-modified peptides, preferably together with a suitable carrier
and adjuvant as an immunotherapy or "anti-atherosclerosis "vaccine"
for prevention and treatment of ischemic cardiovascular
disease.
[0005] 2. Description of the Prior Art
[0006] The protective effects of humoral immunity are known to be
mediated by a family of structurally related glycoproteins called
antibodies. Antibodies initiate their biological activity by
binding to antigens. Antibody binding to antigens is generally
specific for one antigen and the binding is usually of high
affinity. Antibodies are produced by B-lymphocytes. Blood contains
many different antibodies, each derived from a clone of B-cells and
each having a distinct structure and specificity for antigen.
Antibodies are present on the surface of B-lymphocytes, in the
plasma, in interstitial fluid of the tissues and in secretory
fluids such as saliva and mucous on mucosal surfaces.
[0007] All antibodies are similar in their overall structure,
accounting for certain similarities in physico-chemical features
such as charge and solubility. All antibodies have a common core
structure of two identical light chains, each about 24 kilodaltons,
and two identical heavy chains of about 55-70 kilodaltons each. One
light chain is attached to each heavy chain, and the two heavy
chains are attached to each other. Both the light and heavy chains
contain a series of repeating homologous units, each of about 110
amino acid residues in length which fold independently in a common
globular motif, called an immunoglobulin (Ig) domain. The region of
an antibody formed by the association of the two heavy chains is
hydrophobic. Antibodies, and especially monoclonal antibodies, are
known to cleave at the site where the light chain attaches to the
heavy chain when they are subjected to adverse physical or chemical
conditions. Because antibodies contain numerous cysteine residues,
they have many cysteine-cysteine disulfide bonds. All Ig domains
contain two layers of beta-pleated sheets with three or four
strands of anti-parallel polypeptide chains.
[0008] Despite their overall similarity, antibody molecules can be
divided into a small number of distinct classes and subclasses
based on physicochemical characteristics such as size, charge and
solubility, and on their behavior in binding to antigens. In
humans, the classes of antibody molecules are: IgA, IgD, IgE, IgG
and IgM. Members of each class are said to be of the same isotype.
IgA and IgG isotypes are further subdivided into subtypes called
IgA1, IgA2 and IgG1, IgG2, IgG3 and IgG4. The heavy chains of all
antibodies in an isotype share extensive regions of amino acid
sequence identity, but differ from antibodies belonging to other
isotypes or subtypes. Heavy chains are designated by the letters of
the Greek alphabet corresponding to the overall isotype of the
antibody, e.g., IgA contains .alpha., IgD contains .delta., IgE
contains .epsilon., IgG contains .gamma., and IgM contains .mu.
heavy chains. IgG, IgE and IgD circulate as monomers, whereas
secreted forms of IgA and IgM are dimers or pentamers,
respectively, stabilized by the J chain. Some IgA molecules exist
as monomers or trimers.
[0009] There are between 10.sup.8 and 10.sup.10 structurally
different antibody molecules in every individual, each with a
unique amino acid sequence in their antigen combining sites.
Sequence diversity in antibodies is predominantly found in three
short stretches within the amino terminal domains of the heavy and
light chains called variable (V) regions, to distinguish them from
the more conserved constant (C) regions.
[0010] Atherosclerosis is a chronic disease that causes a
thickening of the innermost layer (the intima) of large and
medium-sized arteries. It decreases blood flow and may cause
ischemia and tissue destruction in organs supplied by the affected
vessel. Atherosclerosis is the major cause of cardiovascular
disease including myocardial infarction, stroke and peripheral
artery disease. It is the major cause of death in the western world
and is predicted to become the leading cause of death in the entire
world within two decades.
[0011] The disease is initiated by accumulation of lipoproteins,
primarily low-density lipoprotein (LDL), in the extracellular
matrix of the vessel. These LDL particles aggregate and undergo
oxidative modification. Oxidized LDL is toxic and cause vascular
injury. Atherosclerosis represents in many respects a response to
this injury including inflammation and fibrosis.
[0012] In 1989 Palinski and coworkers identified circulating
autoantibodies against oxidized LDL in humans. This observation
suggested that atherosclerosis may be an autoimmune disease caused
by immune reactions against oxidized lipoproteins. At this time
several laboratories began searching for associations between
antibody titers against oxidized LDL and cardiovascular disease.
However, the picture that emerged from these studies was far from
clear. Antibodies existed against a large number of different
epitopes in oxidized LDL, but the structure of these epitopes was
unknown. The term "oxidized LDL antibodies" thus referred to an
unknown mixture of different antibodies rather than to one specific
antibody. T cell-independent IgM antibodies were more frequent than
T-cell dependent IgG antibodies.
[0013] Antibodies against oxidized LDL were present in both
patients with cardiovascular disease and in healthy controls.
Although some early studies reported associations between oxidized
LDL antibody titers and cardiovascular disease, others were unable
to find such associations. A major weakness of these studies was
that the ELISA tests used to determine antibody titers used
oxidized LDL particles as ligand. LDL composition is different in
different individuals, the degree of oxidative modification is
difficult both to control and assess and levels of antibodies
against the different epitopes in the oxidized LDL particles can
not be determined. To some extent, due to the technical problems it
has been difficult to evaluate the role of antibody responses
against oxidized LDL using the techniques available so far, but,
however, it is not possible to create well defined and reproducible
components of a vaccine if one should use intact oxidized LDL
particles.
[0014] Another way to investigate the possibility that autoimmune
reactions against oxidized LDL in the vascular wall play a key role
in the development of atherosclerosis is to immunize animals
against its own oxidized LDL. The idea behind this approach is that
if autoimmune reactions against oxidized LDL are reinforced using
classical immunization techniques this would result in increased
vascular inflammation and progressive of atherosclerosis. To test
this hypothesis rabbits were immunized with homologous oxidized LDL
and then induced atherosclerosis by feeding the animals a
high-cholesterol diet for 3 months.
[0015] However, in contrast to the original hypothesis immunization
with oxidized LDL had a protective effect reducing atherosclerosis
with about 50%. Similar results were also obtained in a subsequent
study in which the high-cholesterol diet was combined with vascular
balloon-injury to produce a more aggressive plaque development. In
parallel with our studies several other laboratories reported
similar observations. Taken together the available data clearly
demonstrates that there exist immune reactions that protect against
the development of atherosclerosis and that these involves
autoimmunity against oxidized LDL.
[0016] These observations also suggest the possibility of
developing an immune therapy or "vaccine" for treatment of
atherosclerosis-based cardiovascular disease in man. One approach
to do this would be to immunize an individual with his own LDL
after it has been oxidized by exposure to for example copper.
However, this approach is complicated by the fact that it is not
known which structure in oxidized LDL that is responsible for
inducing the protective immunity and if oxidized LDL also may
contain epitopes that may give rise to adverse immune
reactions.
[0017] The identification of epitopes in oxidized LDL is important
for several aspects:
[0018] First, one or several of these epitopes are likely to be
responsible for activating the anti-atherogenic immune response
observed in animals immunized with oxidized LDL. Peptides
containing these epitopes may therefore represent a possibility for
development of an immune therapy or "atherosclerosis vaccine" in
man. Further, they can be used for therapeutic treatment of
atherosclerosis developed in man.
[0019] Secondly, peptides containing the identified epitopes can be
used to develop ELISAs able to detect antibodies against specific
structure in oxidized LDL. Such ELISAs would be more precise and
reliable than ones presently available using oxidized LDL particles
as antigen. It would also allow the analyses of immune responses
against different epitopes in oxidized LDL associated with
cardiovascular disease.
[0020] U.S. Pat. No. 5,972,890 relates to a use of peptides for
diagnosing atherosclerosis. The technique presented in said U.S.
patent is as a principle a form of radiophysical diagnosis. A
peptide sequence is radioactively labelled and is injected into the
bloodstream. If this peptide sequence should be identical with
sequences present in apolipoprotein B it will bind to the tissue
where there are receptors present for apolipoprotein B. In vessels
this is above all atherosclerotic plaque. The concentration of
radioactivity in the wall of the vessel can then be determined
e.g., by means of a gamma camera. The technique is thus a
radiophysical diagnostic method based on that radioactively
labelled peptide sequences will bound to their normal tissue
receptors present in atherosclerotic plaque and are detected using
an external radioactivity analysis. It is a direct analysis method
to identify atherosclerotic plaque. It requires that the patient be
given radioactive compounds.
[0021] Published studies (Palinski et al., 1995, and George et al.,
1998) have shown that immunisation against oxidised LDL reduces the
development of atherosclerosis. This would indicate that immuno
reactions against oxidised LDL in general have a protecting effect.
The results given herein have, however, surprisingly shown that
this is not always the case. E.g., immunisation using a mixture of
peptides #10, 45, 154, 199, and 240 gave rise to an increase of the
development of atherosclerosis. Immunisation using other peptide
sequences, e.g., peptide sequences #1, and 30 to 34 lacks total
effect on the development of atherosclerosis. The results are
surprising because they provide basis for the fact that immuno
reactions against oxidised LDL, can protect against the
development, contribute to the development of atherosclerosis, and
be without any effect at all depending on which structures in
oxidised LDL they are directed to. These findings make it possible
to develop immunisation methods, which isolate the activation of
protecting immuno reactions. Further, they show that immunisation
using intact oxidised LDL could have a detrimental effect if the
particles used contain a high level of structures that give rise to
atherogenic immuno reactions.
SUMMARY OF THE INVENTION
[0022] The technique of the present invention is based on quite
different principles and methods. In accordance with claim 1 the
invention relates to antibodies raised against oxidized fragments
of apolipoprotein B, which antibodies are used for immunisation
against cardiovascular disease.
[0023] As an alternative to active immunisation, using the
identified peptides described above, passive immunisation with
pre-made antibodies directed to the same peptides is an attractive
possibility. Such antibodies may be given desired properties
concerning e.g. specificity and crossreactivity, isotype, affinity
and plasma half-life. The possibility to develop antibodies with
predetermined properties became apparent already with the advent of
the monoclonal antibody technology (Milstein and Kohler, 1975
Nature, 256:495-7). This technology used murine hybridoma cells
producing large amounts of identical, but murine, antibodies. In
fact, a large number of preclinical, and also clinical trials were
started using murine monoclonal antibodies for treatment of e.g.
cancers. However, due to the fact that the antibodies were of
non-human origin the immune system of the patients recognised them
as foreign and developed antibodies to them. As a consequence the
efficacy and plasma half-lives of the murine antibodies were
decreased, and often side effects from allergic reactions, caused
by the foreign antibody, prevented successful treatment.
[0024] To solve these problems several approaches to reduce the
murine component of the specific and potentially therapeutic
antibody were taken. The first approach comprised technology to
make so called chimearic antibodies where the murine variable
domains of the antibody were transferred to human constant regions
resulting in an antibody that was mainly human (Neuberger et al.
1985, Nature 314:268-70). A further refinement of this approach was
to develop humanised antibodies where the regions of the murine
antibody that contacted the antigen, the so called Complementarity
Determining Regions (CDRs) were transferred to a human antibody
framework. Such antibodies are almost completely human and seldom
cause any harmful antibody responses when administered to patients.
Several chimearic or humanised antibodies have been registered as
therapeutic drugs and are now widely used within various
indications (Borrebaeck and Carlsson, 2001, Curr. Opin. Pharmacol.
1:404-408).
[0025] Today also completely human antibodies may be produced using
recombinant technologies. Typically large libraries comprising
billions of different antibodies are used. In contrast to the
previous technologies employing chimearisation or humanisation of
e.g. murine antibodies this technology does not rely on
immunisation of animals to generate the specific antibody. In stead
the recombinant libraries comprise a huge number of pre-made
antibody variants why it is likely that the library will have at
least one antibody specific for any antigen. Thus, using such
libraries the problem becomes the one to find the specific binder
already existing in the library, and not to generate it through
immunisations. In order to find the good binder in a library in an
efficient manner, various systems where phenotype i.e. the antibody
or antibody fragment is linked to its genotype i.e. the encoding
gene have been devised. The most commonly used such system is the
so called phage display system where antibody fragments are
expressed, displayed, as fusions with phage coat proteins on the
surface of filamentous phage particles, while simultaneously
carrying the genetic information encoding the displayed molecule
(McCafferty et al., 1990, Nature 348:552-554). Phage displaying
antibody fragments specific for a particular antigen may be
selected through binding to the antigen in question. Isolated phage
may then be amplified and the gene encoding the selected antibody
variable domains may optionally be transferred to other antibody
formats as e.g. full length immunoglobulin and expressed in high
amounts using appropriate vectors and host cells well known in the
art.
[0026] The format of displayed antibody specificities on phage
particles may differ. The most commonly used formats are Fab
(Griffiths et al., 1994. EMBO J. 13:3245-3260) and single chain
(scFv) (Hoogenboom et al., 1992, J Mol. Biol. 227:381-388) both
comprising the variable antigen binding domains of antibodies. The
single chain format is composed of a variable heavy domain (VH)
linked to a variable light domain (VL) via a flexible linker (U.S.
Pat. No. 4,946,778). Before use as analytical reagents, or
therapeutic agents, the displayed antibody specificity is
transferred to a soluble format e.g. Fab or scFv and analysed as
such. In later steps the antibody fragment identified to have
desirable characteristics may be transferred into yet other formats
such as full length antibodies.
[0027] Recently a novel technology for generation of variability in
antibody libraries was presented (WO98/32845, Soderlind et al.,
2000, Nature BioTechnol. 18:852-856). Antibody fragments derived
from this library all have the same framework regions and only
differ in their CDRs. Since the framework regions are of germline
sequence the immunogenicity of antibodies derived from the library,
or similar libraries produced using the same technology, are
expected to be particularly low (Soderlind et al., 2000, Nature
BioTechnol. 18:852-856). This property is expected to be of great
value for therapeutic antibodies reducing the risk for the patient
to form antibodies to the administered antibody thereby reducing
risks for allergic reactions, the occurrence of blocking
antibodies, and allowing a long plasma half-life of the antibody.
Several antibodies derived from recombinant libraries have now
reached into the clinic and are expected to provide therapeutic
drugs in the near future.
[0028] Thus, when met with the challenge to develop therapeutic
antibodies to be used in humans the art teaches away from the
earlier hybridoma technology and towards use of modern recombinant
library technology (Soderlind et al., 2001, Comb. Chem. & High
Throughput Screen. 4:409-416). It was realised that the peptides
identified (PCT/SE02/00679), and being a integral part of this
invention, could be used as antigens for generation of fully human
antibodies with predetermined properties. In contrast to earlier
art (U.S. Pat. No. 6,225,070) the antigenic structures i.e. the
peptides used in the present invention were identified as being
particularly relevant as target sequences for therapeutic
antibodies (PCT/SE02/00679). Also, in the present invention the
antibodies are derived from antibody libraries omitting the need
for immunisation of lipoprotein deficient mice to raise murine
antibodies (U.S. Pat. No. 6,225,070). Moreover, the resulting
antibodies are fully human and are not expected to generate any
undesired immunological reaction when administered into
patients.
[0029] The peptides used, and previously identified
(PCT/SE02/00679) are the following:
TABLE-US-00001 TABLE 1 A. High IgG, MDA-difference P 11.
FLDTVYGNCSTHFTVKTRKG (SEQ. ID NO: 39) P 25. PQCSTHILQWLKRVHANPLL
(SEQ. ID NO: 40) P 74. VISIPRLQAEARSEILAHWS (SEQ. ID NO: 41) B.
High IgM, no MDA-difference P 40. KLVKEALKESQLPTVMDFRK (SEQ. ID NO:
42) P 68. LKFVTQAEGAKQTEATMTFK (SEQ. ID NO: 43) P 94.
DGSLRHKFLDSNIKFSHVEK (SEQ. ID NO: 44) P 99. KGTYGLSCQRDPNTGRLNGE
(SEQ. ID NO: 45) P 100. RLNGESNLRFNSSYLQGTNQ (SEQ. ID NO: 46) P
102. SLTSTSDLQSGIIKNTASLK (SEQ. ID NO: 47) P 103.
TASLKYENYELTLKSDTNGK (SEQ. ID NO: 48) P 105. DMTFSKQNALLRSEYQADYE
(SEQ. ID NO: 49) P 177. MKVKIIRTIDQMQNSELQWP (SEQ. ID NO: 50) C.
High IgG, no MDA difference P 143. IALDDAKINFNEKLSQLQTY (SEQ. ID
NO: 51) P 210. KTTKQSFDLSVKAQYKKNKH (SEQ. ID NO: 52) D. NHS/AHP,
IgG-ak > 2, MDA-difference P1. EEEMLENVSLVCPKDATRFK (SEQ. ID NO:
53) P 129. GSTSHHLVSRKSISAALEHK (SEQ. ID NO: 54) P 148.
IENIDFNKSGSSTASWIQNV (SEQ. ID NO: 55) P 162. IREVTQRLNGEIQALELPQK
(SEQ. ID NO: 56) P 252. EVDVLTKYSQPEDSLIPFFE (SEQ. ID NO: 57) E.
NHS/AHP, IgM-ak > 2, MDA-difference P 301. HTFLIYITELLKKLQSTTVM
(SEQ. ID NO: 58) P 30. LLDIANYLMEQIQDDCTGDE (SEQ. ID NO: 59) P 31.
CTGDEDYTYKIKRVIGNMGQ (SEQ. ID NO: 60) P 32. GNMGQTMEQLTPELKSSILK
(SEQ. ID NO: 61) P 33. SSILKCVQSTKPSLMIQKAA (SEQ. ID NO: 62) P 34.
IQKAAIQALRKMEPKDKDQE (SEQ. ID NO: 63) P 100. RLNGESNLRFNSSYLQGTNQ
(SEQ. ID NO: 64) P 107. SLNSHGLELNADILGTDKIN (SEQ. ID NO: 65) P
149. WIQNVDTKYQIRIQIQEKLQ (SEQ. ID NO: 66) P 169.
TYISDWWTLAAKNLTDFAEQ (SEQ. ID NO: 67) P 236. EATLQRIYSLWEHSTKNHLQ
(SEQ. ID NO: 68) F. NHS/AHP, IgG-ak < 0.5, no MDA-difference P
10. ALLVPPETEEAKQVLFLDTV (SEQ. ID NO: 69) P 45.
IEIGLEGKGFEPTLEALFGK (SEQ. ID NO: 70) P 111. SGASMKLTTNGRFREHNAKF
(SEQ. ID NO: 71) P 154. NLIGDFEVAEKINAFRAKVH (SEQ. ID NO: 72) P
199. GHSVLTAKGMALFGEGKAEF (SEQ. ID NO: 73) P 222.
FKSSVITLNTNAELFNQSDI (SEQ. ID NO: 74) P 240. FPDLGQEVALNANTKNQKIR
(SEQ. ID NO: 75)
or an active site of one or more of these peptides.
[0030] In Table 1 above, the following is due:
(A) Fragments that produce high levels of IgG antibodies to
MDA-modified peptides (n=3), (B) Fragments that produce high levels
of IgM antibodies, but no difference between native and
MDA-modified peptides (n=9), (C) Fragments that produce high levels
of IgG antibodies, but no difference between native and
MDA-modified peptides (n=2), (D) Fragments that produce high levels
of IgG antibodies to MDA-modified peptides and at least twice as
much antibodies in the NHP-pool as compared to the AHP-pool (n=5),
(E) Fragments that produce high levels of IgM antibodies to
MDA-modified peptides and at least twice as much antibodies in the
NHP-pool as compared to the AHP-pool (n=11), and (F) Fragments that
produce high levels of IgG antibodies, but no difference between
intact and MDA-modified peptides but at least twice as much
antibodies in the AHP-pool as compared to the NHP-pool (n=7).
[0031] The present invention relates to the use of at least one
recombinant human antibody or an antibody fragment thereof directed
towards at least one oxidized fragment of apolipoprotein B in the
manufacture of a pharmaceutical composition for therapeutical or
prophylactical treatment of atherosclerosis by means of passive
immunization.
[0032] Further the invention relates to the recombinant preparation
of such antibodies, as well as the invention relates to method for
passive immunization using such antibodies raised using an oxidized
apolipoprotein B fragment, as antigen, in particular a fragment as
identified above.
[0033] The present invention utilises a recombinant antibody
fragment library to generate specific human antibody fragments
against oxidized, in particular MDA modified peptides derived from
Apo B100. Identified antibody fragments with desired
characteristics may then rebuilt into full length human
immunoglobulin to be used for therapeutic purposes.
BRIEF DESCRIPTION OF THE DRAWINGS
[0034] FIGS. 1A-1C are ELISA results from Screen II;
[0035] FIGS. 2A-2F are graphs of dose response for ELISAs;
[0036] FIG. 3 are the DNA sequences of various regions;
[0037] FIGS. 4A and 4B are light and heavy-chain vectors;
[0038] FIG. 5 is a graph of ELISA results;
[0039] FIG. 6 is a graph of Oil Red 0 Stained area in aortas;
[0040] FIG. 7 is a graph of Oil Red 0 stained area in aortas versus
antibody product;
[0041] FIGS. 8a and 8b are graphs of LDL uptake; and
[0042] FIG. 9 are graphs of the Ratio MDA/na LDL and ApoB
DETAILED DESCRIPTION OF THE INVENTION
[0043] Below will follow a detailed description of the invention
exemplified by, but not limited to, human antibodies derived from a
recombinant antibody fragment library and directed towards two MDA
modified peptides from ApoB 100.
EXAMPLE 1
Selection of scFv Against MDA Modified Peptides IEIGL EGKGF EPTLE
ALFGK (SEQ. ID NO: 70) (P45, Table 1) and KTTKQ SFDLS VKAQY KKNKH
(P210, Table 1)
[0044] The target antigens were chemically modified to carry
Malone-di-aldehyde (MDA) groups on lysines and histidines. The
modified peptides were denoted IEI (P45) and KTT (P210).
[0045] Selections were performed using BioInvent's n-CoDeR.TM.scFv
library for which the principle of construction and production have
been described in Soderlind et al. 2000, Nature BioTechnology. 18,
852-856. The library contains approximately 2.times.10.sup.10
independent clones and a 2000 fold excess of clones were used as
input for each selection. Selections were performed in three
rounds. In selection round 1, Immunotubes (NUNC
Maxisorb.TM.-444202) were coated with 1.2 ml of 20 g/ml
MDA-modified target peptides in PBS (137 mM NaCl, 2.7 mM KCl, 4.3
mM Na.sub.2HPO.sub.4, 1.4 mM KH.sub.2PO.sub.4) with end over end
agitation at +4.degree. C. over night. The tubes were then blocked
with TPBSB5% (5% BSA, 0.05% Tween 20, 0.02% sodium Azide in PBS)
for 30 minutes and washed twice with TPBSB3% (3% BSA, 0.05% Tween
20, 0.02% sodium Azide in PBS) before use. Each target tube was
then incubated with approximately 2.times.10.sup.13 CFU phages from
the n-CodeR.TM. library in 1.8 ml TPBSB3% for 2 h at room
temperature, using end over end agitation. The tubes were then
washed with 15.times.3 ml TPBSB3% and 2.times.1 ml PBS before the
bound phages were eluted with 1 ml/tube of 2 mg/ml trypsin (Roche,
109819) for 30 minutes at room temperature. This procedure takes
advantage of a specific trypsin site in the scFv-fusion protein to
release the phage from the target. The reaction was stopped by the
addition of 100 of Aprotein (0.2 mg/ml, Roche, cat.236624), and the
immunotubes were washed with 300 ul PBS, giving a final volume of
1.4 ml.
[0046] For amplification of the selected phage E. Coli HB101F'
cells were grown exponentially in 10 ml of LB medium (Merck, cat.
1.10285) to OD.sub.600=0.5 and infected with the selected and
eluted phage principally as described (Soderlind et al., 2000,
Nature BioTechnol. 18, 852-856. The resulting phage supernatant was
then precipitated by addition of 1/4 volume of 20% PEG.sub.6000 in
2.5 M NaCl and incubated for 5 h at +4.degree. C. The phages were
then pelleted by centrifugation for 30 minutes, 13000.times.g,
re-suspended in 500 l PBS and used in selection round 2.
[0047] The amplified phagestock was used in selection round 2 in a
final volume of 1.5 ml of 5% BSA, 0.05% Tween 20, 0.02% sodium
Azide in PBS. Peptide without MDA modification (4.times.10.sup.-7
M) was also included for competition against binders to
MDA-unmodified target peptide. The mixture was incubated in
immunotubes prepared with antigen as described above, except that
the tubes were blocked with 1% Casein instead of TPBSB3%. The
incubations and washing of the immunotubes were as described for
selection 1. Bound phages were then eluted for 30 minutes using 600
l of 100 mM Tris-Glycine buffer, pH 2.2. The tubes were washed with
additional 200 l glycin buffer and the eluates were pooled and then
neutralised with 96 l of 1 M Tris-HCl, pH 8.0. The samples were
re-natured for 1 h at room temperature and used for selection round
3.
[0048] For selection round 3, BSA, Tween 20 and Sodium Azide were
added to the renaturated phage pool to a final concentration of 3%,
0.05% and 0.02%, respectively. Competitor peptides, MDA modified
unrelated peptides as well as native target peptides without
modification were added to a concentration of 1.times.10.sup.-7M.
The phage mixtures (1100 l) were added to immunotubes coated with
target antigen as described in selection 1 and incubated over night
at 4.degree. C. with agitation. The tubes were then washed with
3.times.3 ml TPBSB 3%, 5.times.3 ml PBS and eventually bound phages
were eluted using trypsin as described in selection round 1 above.
Each eluate was infected to 10 ml of logarithmically growing
HB101F' in LB containing 100 g/ml ampicillin, 15 g/ml tetracycline,
0.1% glucose, and grown over night at 30.degree. C., 200 rpm in a
shaker incubator.
[0049] The over night cultures were used for mini scale preparation
of plasmid DNA, using Biorad mini prepp Kit (Cat. 732 6100). To
remove the phage gene III part from the expression vector, 0.25 g
of the plasmid DNA was cut for 2 h at 37.degree. C. using 2.5 U
Eag-1 (New England Biolabs, cat. R050) in the buffer recommended by
the supplier. The samples were then heat inactivated for 20 minutes
at 65.degree. C. and ligated over night at 16.degree. C. using 1 U
T4 DNA ligase in 30 l of 1.times. ligase buffer (Gibco/BRL). This
procedure will join two Eag-1 sites situated on opposite sides of
the phage gene III fragment, thus creating a free scFv displaying a
terminal 6xhis tag. After ligation the material was digested for 2
h at 37.degree. C. in a solution containing 30 ul ligation mix, 3.6
l 10.times.REACT3 stock, 0.4 l 1 M NaCl, 5 l H.sub.2O.sub.2, in
order to destroy clones in which the phage gene III segment had
been religated. Twenty (20) ng of the final product were
transformed into chemical competent Top10F' and spread on 500
cm.sup.2 Q-tray LA-plates (100 .mu.g/ml Amp, 1% glucose), to enable
the picking of single colonies for further screening.
Screening of the n-CoDeR.TM.scFv Library for Specific Antibody
Fragments Binding T0 MDA Modified Peptides from Apolipoprotein
B-100
[0050] In order to identify scFv that could discriminate between
MDA modified IEI (P45) peptide and native IEI and between MDA
modified KTT (P210) and native KTT respectively screenings were
performed on bacterial supernatants from selected scFv expressing
clones.
[0051] Colony picking of single clones, expression of scFv and
screening number 1 was performed on BioInvent's automatic system
according to standard methods. 1088 and 831 single clones selected
against the MDA modified IEI and KTT peptides respectively were
picked and cultured and expressed in micro titre plates in 100 l LB
containing 100 g ampicillin/ml.
[0052] For screening number 1 white Assay plates (Greiner 655074)
were coated with 54 pmol peptide/well in coating buffer (0.1 M
Sodium carbonate, pH 9.5), either with MDA modified peptide which
served as positive target or with corresponding unmodified peptide
which served as non target. In the ELISA the expressed scFv were
detected through a myc-tag situated C-terminal to the scFv using 1
g/ml of anti-c-myc monoclonal (9E10 Roche 1667 149) in wash buffer.
As a secondary antibody Goat-anti-mouse alkaline phosphatase
conjugate (Applied Biosystems Cat # AC32ML) was used at 25000 fold
dilution. For luminescence detection CDP-Star Ready to use with
Emerald II.TM.-Tropix.RTM.-(Applied Biosystems Cat # MS100RY) were
used according to suppliers recommendation.
[0053] ScFv clones that bound MDA modified peptide but not native
peptide were re expressed as described above and to screening
another time in a luminescent ELISA (Table 2 and FIG. 1). Tests
were run both against directly coated peptides (108 pmol/well
coated with PBS) and the more physiological target, LDL particles
(1 g/well coated in PBS+1 mM EDTA) containing the ApoB-100 protein
with and without MDA modification were used as targets. Positive
clones were those that bound oxidised LDL and MDA modified peptide
but not native LDL or peptide. The ELISA was performed as above
except that the anti-His antibody (MaB050 R.alpha.D) was used as
the detection antibody. Twelve IEI clones and 2 KTT clones were
found to give more than three fold higher luminescence signal at
700 nm for the MDA modified form than for the native form both for
the peptide and LDL.
[0054] The identified clones were further tested through titration
against a fixed amount (1 g/well) of MDA LDL and native LDL in
order to evaluate the dose response of the scFv (FIG. 2).
TABLE-US-00002 TABLE 2 Screening results. The number of clones
tested in each screening step for each target. The scored hits in
percent are shown within brackets. Target IEI KTT Screening Tested
Clones 1088 831 number 1 Scored Hits 64 33 (%) (5.9%) (4.0%)
Screening Tested Clones 64 33 number 2 Scored Hits 12 2 (%) (1.1%)
(0.2%) Dose Tested Clones 12 2 response Scored Hits 8 2 (%) (0.7%)
(0.2%)
[0055] The sequences of the chosen scFv clones were determined in
order to find unique clones. Bacterial PCR was performed with the
Boeringer Mannheim Expand kit using primers (5'-CCC AGT CAC GAC GTT
GTA AAA CG-3') (SEQ. ID NO: 76) and (5'-GAA ACA GCT ATG AAA TAC CTA
TTG C-3') (SEQ. ID NO: 77) and a GeneAmp PCR system 9700 (PE
Applied system) using the temperature cycling program 94.degree. C.
5 min, 30 cycles of 94.degree. C. 30 s, 52.degree. C. for 30 s and
68.degree. C. for 2 min and finally 5 min at 68 min. The sequencing
reaction was performed with the bacterial PCR product (five fold
diluted) as template, using Big Dye Terminator mix from PE Applied
Biosystems and the GeneAmp PCR system 9700 (PE Applied system) and
the temperature cycling program 25 cycles of 96.degree. C. 10 s,
50.degree. C. for 5 s and 60.degree. C. for 4 min. The extension
products were purified according to the supplier's instructions and
the separation and detection of extension products was done by
using a PRISM.RTM. 3100 Genetic analyser (PE Applied Biosystems).
The sequences were analysed by the in house computer program. From
the sequence information homologous clones and clones with
inappropriate restriction sites were excluded, leaving six clones
for IgG conversion. The DNA sequence of the variable heavy (VH) and
variable light (VL) domains of the finally selected clones are
shown in FIG. 3.
EXAMPLE 2
Transfer of Genes Encoding the Variable Parts of Selected scFv to
Full Length Human IgG1 Vestors
[0056] Bacteria containing scFv clones to be converted to Ig-format
were grown over night in LB supplemented with 100 g/ml ampicillin.
Plasmid DNA was prepared from over night cultures using the Quantum
Prep, plasmid miniprep kit from Biorad (# 732-6100). The DNA
concentration was estimated by measuring absorbance at 260 nm, and
the DNA was diluted to a concentration of 2 ng/l.
[0057] VH and VL from the different scFv-plasmids were PCR
amplified in order to supply these segments with restriction sites
compatible with the expression vectors (see below). 5' primers
contain a BsmI and 3' primers contain a BsiWI restriction enzyme
cleavage site (shown in italics). 3' primers also contained a
splice donor site (shown in bold).
Primers for Amplification of VH-Segments:
TABLE-US-00003 [0058] 5'VH: (SEQ. ID. NO: 13)
5'-GGTGTGCATTCCGAGGTGCAGCTGTTGGAG 3'VH: (SEQ. ID. NO: 14)
5'-GACGTACGACTCACCTGAGCTCACGGTGACCAG
Primers for Amplification of VL-Segments:
TABLE-US-00004 [0059] 5'VL: (SEQ. ID. NO: 15)
5'-GGTGTGCATTCCCAGTCTGTGCTGACTCAG 3'VL: (SEQ. ID. NO: 16)
5'-GACGTACGTTCTACTCACCTAGGACCGTCAGCTT
[0060] PCR was conducted in a total volume of 50 .mu.l, containing
10 ng template DNA, 0.4 .quadrature.M 5' primer, 0.4 M 3' primer
and 0.6 mM dNTP (Roche, #1 969 064). The polymerase used was Expand
long template PCR system (Roche # 1 759 060), 3.5 upper reaction,
together with each of the supplied buffers in 3 separate reactions.
Each PCR amplification cycle consisted of a denaturing step at
94.degree. C. for 30 seconds, an annealing step at 55.degree. C.
for 30 seconds, and an elongating step at 68.degree. C. for 1.5
minutes. This amplification cycle was repeated 25 times. Each
reaction began with a single denaturing step at 94.degree. C. for 2
minutes and ended with a single elongating step at 68.degree. C.
for 10 minutes. The existence of PCR product was checked by agarose
gel electrophoresis, and reactions containing the same amplified
material (from reactions with different buffers) were pooled. The
PCR amplification products were subsequently purified by spin
column chromatography using S400-HR columns (Amersham-Pharmacia
Biotech # 27-5240-01).
[0061] Four (4) l of from each pool of PCR products were used for
TOPO.RTM.-TA cloning (pCR 2.1 TOPO.RTM.-, InVitrogen #K4550-01)
according to the manufacturers recommendations. Bacterial colonies
containing plasmids with inserts were grown over night in LB
supplemented with 100 g/ml ampicillin and 20 g/ml kanamycin.
Plasmid DNA was prepared from over night cultures using the Quantum
Prep, plasmid miniprep kit from Biorad (# 732-6100). Plasmid
preparations were purified by spin column chromatography using
S400-HR columns (Amersham-Pharmacia Biotech # 27-5240-01). Three
plasmids from each individual VH and VL cloning were subjected to
sequence analysis using BigDye.RTM.-Cycle Sequencing (Perkin Elmer
Applied Biosystem, # 4303150). The cycle sequencing program
consisted of a denaturing step at 96.degree. C. for 10 seconds, an
annealing step at 50.degree. C. for 15 seconds, and an elongating
step at 60.degree. C. for 4 minutes. This cycle was repeated 25
times. Each reaction began with a single denaturing step at
94.degree. C. for 1 minute. The reactions were performed in a
volume of 10 l consisting of 1 M primer 5'-CAGGAAACAGCTATGAC (SEQ.
ID NO:78), 3 l plasmid DNA and 4 l Big Dye.RTM.-reaction mix. The
reactions were precipitated according to the manufacturer's
recommendations, and samples were run on a ABI PRISM.RTM.-3100
Genetic Analyzer. Sequences were compared to the original scFv
sequence using the alignment function of the OMIGA sequence
analysis software (Oxford Molecular Ltd).
[0062] Plasmids containing VH and VL segments without mutations
were restriction enzyme digested. To disrupt the pCR 2.1 TOPO.RTM.
vector, plasmids were initially digested with DraI (Roche # 1 417
983) at 37.degree. C. for 2 hours. Digestions were heat inactivated
at 70.degree. C. for 20 minutes and purified by spin column
chromatography using S400-HR columns (Amersham-Pharmacia Biotech #
27-5240-01). The purified DraI digestions were subsequently
digested with BsmI (Roche # 1 292 307) and BsiWI (Roche # 1 388
959) at 55.degree. C. over night. Digestions were purified using
phenol extraction and precipitation. The precipitated DNA was
dissolved in 10 l H.sub.2O and used for ligation.
[0063] The expression vectors were obtained from Lars Norderhaug
(J. Immunol. Meth. 204 (1997) 77-87). After some modifications, the
vectors (FIG. 4) contain a CMV promoter, an Ig-leader peptide, a
cloning linker containing BsmI and BsiWI restriction sites for
cloning of VH/VL, genomic constant regions of IgG1 (heavy chain
(HC) vector) or lambda (light chain (LC) vector), neomycin (HC
vector) or methotrexate (LC vector) resistance genes for selection
in eukaryotic cells, SV40 and ColEI origins of replication and
ampicillin (HC vector) or kanamycin (LC vector) resistance genes
for selection in bacteria.
[0064] The HC and LC vectors were digested with BsmI and BsiWI,
phosphatase treated and purified using phenol extraction and
precipitation. Ligation were set up at 16.degree. C. over night in
a volume of 10 l, containing 100 ng digested vector, 2 l digested
VH/VL-pCR 2.1 TOPO.RTM.-vector (see above), 1 U T4 DNA ligase (Life
Technologies, # 15224-025) and the supplied buffer. 2 l of the
ligation mixture were subsequently transformed into 50 l
chemocompetent top10F' bacteria, and plated on selective (100 g/ml
ampicillin or 20 g/ml kanamycin) agar plates.
[0065] Colonies containing HC/LC plasmids with VH/VL inserts were
identified by colony PCR:
TABLE-US-00005 Forward primer: 5'-ATGGGTGACAATGACATC (SEQ. ID NO:
17) Reverse primer: 5'-AAGCTTGCTAGCGTACG (SEQ. ID NO: 18)
[0066] PCR was conducted in a total volume of 20 l, containing
bacterias, 0.5 M forward primer, 0.5 M reverse primer and 0.5 mM
dNTP (Roche, #1 969 064). The polymerase used was Expand long
template PCR system (Roche # 1 759 060), 0.7 Upper reaction,
together with the supplied buffer #3. Each PCR amplification cycle
consisted of a denaturing step at 94.degree. C. for 30 seconds, an
annealing step at 52.degree. C. for 30 seconds, and an elongating
step at 68.degree. C. for 1.5 minutes. This amplification cycle was
repeated 30 times. Each reaction began with a single denaturing
step at 94.degree. C. for 2 minutes and ended with a single
elongating step at 68.degree. C. for 5 minutes. The existence of
PCR product was checked by agarose gel electrophoresis. Colonies
containing HC/LC plasmids with VH/VL inserts were grown over night
in LB supplemented with 100 g/ml ampicillin or 20 g/ml kanamycin.
Plasmid DNA was prepared from over night cultures using the Quantum
Prep, plasmid miniprep kit from Biorad (# 732-6100). Plasmid
preparations were purified by spin column chromatography using
S400-HR columns (Amersham-Pharmacia Biotech # 27-5240-01). To
confirm the integrity of the DNA sequence, three plasmids from each
individual VH and VL were subjected to sequence analysis using Big
Dye.RTM.-Cycle Sequencing (Perkin Elmer Applied Biosystem, #
4303150). The cycle sequencing program consisted of a denaturing
step at 96.degree. C. for 10 seconds, an annealing step at
50.degree. C. for 15 seconds, and an elongating step at 60.degree.
C. for 4 minutes. This cycle was repeated 25 times. Each reaction
began with a single denaturing step at 94.degree. C. for 1 minute.
The reactions were performed in a volume of 10 l consisting of 1 M
primer (5'-AGACCCAAGCTAGCTTGGTAC) (SEQ. ID NO:79), 3 l plasmid DNA
and 4 .mu.l Big Dye.RTM. reaction mix. The reactions were
precipitated according to the manufacturer's recommendations, and
samples were run on a ABI PRISM.RTM. 3100 Genetic Analyzer.
Sequences were analysed using the OMIGA sequence analysis software
(Oxford Molecular Ltd). The plasmid DNA was used for transient
transfection of COS-7 cells (see below) and were digested for
production of a joined vector, containing heavy- and light chain
genes on the same plasmid.
[0067] Heavy and light chain vectors containing VH and VL segments
originating from the same scFv were cleaved by restriction enzymes
and ligated: HC- and LC-vectors were initially digested with MunI
(Roche # 1 441 337) after which digestions were heat inactivated at
70.degree. C. for 20 minutes and purified by spin column
chromatography using S200-HR columns (Amersham-Pharmacia Biotech #
27-5120-01). HC-vector digestions were subsequently digested with
NruI (Roche # 776 769) and LC-vector digestions with Bst11071
(Roche # 1 378 953). Digestions were then heat inactivated at
70.degree. C. for 20 minutes and purified by spin column
chromatography using S400-HR columns (Amersham-Pharmacia Biotech #
27-5240-01). 5 l of each digested plasmid were ligated at
16.degree. C. over night in a total volume of 20 l, containing 2 U
T4 DNA ligase (Life Technologies, # 15224-025) and the supplied
buffer. 2 l of the ligation mixture were subsequently transformed
into 50 .mu.l chemocompetent top10F' bacteria, and plated on
selective (100 g/ml ampicillin and 20 g/ml kanamycin) agar
plates.
[0068] Bacterial colonies were grown over night in LB supplemented
with 100 g/ml ampicillin and 20 g/ml kanamycin. Plasmid DNA was
prepared from over night cultures using the Quantum Prep, plasmid
miniprep kit from Biorad (# 732-6100). Correctly joined vectors
were identified by restriction enzyme digestion followed by
analyses of fragment sizes by agarose gel-electrophoreses
[0069] Plasmid preparations were purified by spin column
chromatography using S400-HR columns (Amersham-Pharmacia Biotech #
27-5240-01) and used for transient transfection of COS-7 cells.
[0070] COS-7 cells (ATCC # CRL-1651) were cultured at 37.degree. C.
with 5% CO.sub.2 in Dulbeccos MEM, high
glucose+GlutamaxI.TM.-(Invitrogen # 31966021), supplemented with
0.1 mM non-essential amino acids (Invitrogen # 11140035) and 10%
fetal bovine sera (Invitrogen # 12476-024, batch # 1128016). The
day before transfection, the cells were plated in 12-well plates
(Nunc.TM.-, # 150628) at a density of 1.5.times.10.sup.5 cells per
well.
[0071] Prior to transfection, the plasmid DNA was heated at
70.degree. C. for 15 minutes. Cells were transfected with 1 g
HC-plasmid+1 g LC-plasmid, or 2 g joined plasmid per well, using
Lipofectamine.TM.-2000 Reagent (Invitrogen, # 11668019) according
to the manufacturers recommendations. 24 hours post transfection,
cell culture media was changed and the cells were allowed to grow
for 5 days. After that, medium was collected and protein production
was assayed for using ELISA.
[0072] Ninetysix (96)-well plates (Costar # 9018, flat bottom, high
binding) were coated at 4.degree. C. over night by adding 100
l/well rabbit anti-human lamda light chain antibody (DAKO, # A0193)
diluted 4000 times in coating buffer (0.1 M sodium carbonate, pH
9.5). Plates were washed 4 times in PBS containing 0.05% Tween 20
and thereafter blocked with 100 l/well PBS+3% BSA (Albumin,
fraction V, Roche # 735108) for 1 h. at room temperature. After
washing as above, 100 l/well of sample were added and incubated in
room temperature for 1 hour. As a standard for estimation of
concentration, human purified IgG1 (Sigma, # 15029) was used.
Samples and standard were diluted in sample buffer (1.times.PBS
containing 2% BSA and 0.5% rabbit serum (Sigma # R4505).
Subsequently, plates were washed as described above and 100 l/well
of rabbit anti-human IgG (-chain) HRP-conjugated antibody (DAKO, #
P214) diluted 8000 times in sample buffer was added and incubated
at room temperature for 1 hour. After washing 8 times with PBS
containing 0.05% Tween 20, 100 l/well of a substrate solution
containing one OPD tablet (10 mg, Sigma # P8287) dissolved in 15 ml
citric acid buffer and 4.5 l H.sub.2O.sub.2 (30%) was added. After
10 minutes, the reaction was terminated by adding 150 l/well of 1M
HCl. Absorbance was measured at 490-650 nm and data was analyzed
using the Softmax software.
[0073] Bacteria containing correctly joined HC- and LC-vectors were
grown over night in 500 ml LB supplemented with ampicillin and
kanamycin. Plasmid DNA was prepared from over night cultures using
the Quantum Prep, plasmid maxiprep kit from Biorad (# 732-6130).
Vectors were linearized using PvuI restriction enzyme (Roche # 650
129). Prior to transfection, the linearized DNA was purified by
spin column chromatography using S400-HR columns
(Amersham-Pharmacia Biotech # 27-5240-01) and heated at 70.degree.
C. for 15 minutes.
EXAMPLE 3
Stable Transfection of NSO Cells Expressing Antibodies Against MDA
Modified Peptides Form Apolipoprotein B-100
[0074] NS0 cells (ECACC no. 85110503) were cultured in DMEM (cat nr
31966-021, Invitrogen) supplemented with 10% Fetal Bovine Serum
(cat no. 12476-024, lot: 1128016, Invitrogen) and 1.times.NEAA
(non-essential amino acids, cat no. 11140-053, Invitrogen). Cell
cultures are maintained at 37.degree. C. with 5% CO.sub.2 in
humidified environment.
[0075] DNA constructs to be transfected were four constructs of IEI
specific antibodies (IEI-A8, IEI-D8, IEI-E3, IEI-G8), two of KTT
specific antibodies (KTT-B8, KTT-D6) and one control antibody
(JFPA12). The day before transfection, the cells were trypsinized
and counted, before plating them in a T-75 flask at
12.times.10.sup.6cells/flask. On the day of transfection, when the
cells were 85-90% confluent, the cells were plated in 15 ml
DMEM+1.times.NEAA+10% FBS (as above). For each flask of cells to be
transfected, 35-40 .mu.g of DNA were diluted into 1.9 ml of
OPTI-MEM.RTM.-I Reduced Serum Medium (Cat no. 51985-026, lot:
3062314, Invitrogen) without serum. For each flask of cells, 114
.mu.l of Lipofectamine.TM.-2000 Reagent (Cat nr. 11668-019, lot:
1116546, Invitrogen) were diluted into 1.9 ml OPTI-MEM.RTM.-I
Reduced Serum Medium in another tube and incubated for 5 min at
room temperature. The diluted DNA was combined with the diluted
Lipofectamine.TM.-2000 Reagent (within 30 min) and incubated at
room temperature for 20 min to allow DNA-LF2000 Reagent complexes
to form.
[0076] The cells were washed with medium once and 11 ml
DMEM+1.times.NEAA+10% FBS were added. The DNA-LF2000 Reagent
complexes (3.8 ml) were then added directly to each flask and
gently mixed by rocking the flask back and forth. The cells were
incubated at 37.degree. C. in a 5% CO.sub.2 incubator for 24 h.
[0077] The cells were then trypsinized and counted, and
subsequently plated in 96-well plates at 2.times.10.sup.4
cells/well using five 96-well plates/construct. Cells were plated
in 100 l/well of DMEM+1.times.NEAA+10% FBS (as above) containing
G418-sulphate (cat nr.10131-027, lot: 3066651, Invitrogen) at 600
g/ml. The selection pressure was kept unchanged until harvest of
the cells.
[0078] The cells were grown for 12 days and assayed for antibody
production using ELISA. From each construct cells from the 24 wells
containing the highest amounts of IgG were transferred to 24-well
plates and were allowed to reach confluency. The antibody
production from cells in these wells was then assayed with ELISA
and 5-21 pools/construct were selected for re-screening (Table 3).
Finally cells from the best 1-4 wells for each construct were
chosen. These cells were expanded successively in cell culture
flasks and finally transferred into triple layer flasks (500 cm2)
in 200 ml of (DMEM+1.times.NEAA+10% Ultra low IgG FBS (cat.no.
16250-078, lot.no. 113466, Invitrogen)+G418 (600 .mu.g/ml)) for
antibody production. The cells were incubated for 7-10 days and the
supernatants were assayed by ELISA, harvested and sterile filtered
for purification.
EXAMPLE 4
Production and Purification of Human IgG1
[0079] Supernatants from NSO cells transfected with the different
IgG1 antibodies were sterile filtered using a 0.22 .mu.m filter and
purified using an affinity medium MabSelect.TM. with recombinant
protein A, (Cat. No. 17519901 Amersham Biosciences).
[0080] Bound human IgG1 was eluted with HCL-glycine buffer pH 2.8.
The eluate was collected in 0.5 ml fractions and OD.sub.280 was
used to determine presence of protein. The peak fractions were
pooled and absorbance was measured at 280 nm and 320 nm. Buffer was
changed through dialysis against a large volume of PBS. The
presence of endotoxins in the purified IgG-1 preparations was
tested using a LAL test (QCL-1000.RTM.-, cat. No. 50-647U Bio
Whittaker). The samples contained between 1 and 12 EU/ml endotoxin.
The purity of the preparations were estimated to exceed 98% by PAGE
analysis.
TABLE-US-00006 TABLE 3 Summary of Production and Purification of
human IgG1 Volume culture Total IgG1 in Total IgG1 Clone
supernatant supernatant Purified name (ml) (mg) (mg) Yield (%)
IEI-A8 600 68 42 61.8 IEI-D8 700 45 21 46.7 IEI-E3 700 44.9 25.6 60
IEI-G8 600 74 42.4 57.3 KTT-B8 1790 77.3 37.6 48.6 KTT-D6 1845 47.8
31.8 66.5 JFPA12 2000 32.2 19.2 59.6
[0081] The purified IgG1 preparations were tested in ELISA for
reactivity to MDA modified and unmodified peptides (FIG. 5) and
were then used in functional in vitro and in vivo studies.
EXAMPLE 5
Analysis of Possible Anti-Atherogenic Effect of Antibodies are
Performed Both in Experimental Animals and in Cell Culture
Studies
[0082] 1. Effect of Antibodies on Atherosclerosis in Apolipoprotein
E Knockout (apo E-) Mice.
[0083] Five weeks old apo E- mice are fed a cholesterol-rich diet
for 15 weeks. This treatment is known to produce a significant
amount of atherosclerotic plaques in the aorta and carotid
arteries. The mice are then given an intraperitoneal injection
containing 500 g of the respective antibody identified above.
Control mice are given 500 g of an irrelevant control antibody or
PBS alone. Treatments are repeated after 1 and 2 weeks. The mice
are sacrificed 4 weeks after the initial antibody injection. The
severity of atherosclerosis in the aorta is determined by Oil Red O
staining of flat preparations and by determining the size of
subvalvular atherosclerotic plaques. Collagen, macrophage and T
cell content of subvalvular atherosclerotic plaques is determined
by Masson trichrome staining and cell-specific
immunohistochemistry. Quantification of Oil Red O staining, the
size of the subvalvular plaques, trichrome staining and
immunohistochemical staining is done using computer-based image
analysis.
[0084] In a first experiment the effect of the antibodies on
development of atherosclerosis was analysed in apo E-/- mice fed a
high-cholesterol diet. The mice were given three intraperitoneal
injections of 0.5 mg antibody with week intervals starting at 21
weeks of age, using PBS as control. They were sacrificed two weeks
after the last antibody injection, and the extent of
atherosclerosis was assessed by Oil Red O staining of descending
aorta flat preparations. A pronounced effect was observed in mice
treated with the IEI-E3 antibody, with more than 50% reduction of
atherosclerosis as compared to the PBS group (P=0.02) and to a
control group receiving a human IgG1 antibody (FITC8) directed
against a non-relevant fluorescein isothiocynate (FITC) antigen
(P=0.03) (FIG. 6). The mice tolerated the human antibodies well and
no effects on the general health status of the mice were
evident.
[0085] To verify the inhibitory effect of the IEI-E3 antibody on
development of atherosclerosis we then performed a dose-response
study. The schedule was identical to that of the initial study. In
mice treated with IEI-E3 antibodies atherosclerosis was reduced by
2% in the 0.25 mg group (n.s.), by 25% in the 0.5 mg group (n.s.)
and by 41% (P=0.02) in the 2.0 mg group as compared to the
corresponding FITC antibody-treated groups (FIG. 7).
[0086] 2. Effect of antibodies on neo-intima formation following
mechanical injury of carotid arteries in apo E- mice. Mechanical
injury of arteries results in development of fibro-muscular
neo-intimal plaque within 3 weeks. This plaque resembles
morphologically a fibro-muscular atherosclerotic plaque and has
been used as one model for studies of the development of raised
lesion. Placing a plastic collar around the carotid artery causes
the mechanical injury. Five weeks old apo E- mice are fed a
cholesterol-rich diet for 14 weeks. The mice are then given an
intraperitoneal injection containing 500 g of the respective
antibody. Control mice are given 500 g of an irrelevant control
antibody or PBS alone. The treatment is repeated after 7 days and
the surgical placement of the plastic collar is performed 1 day
later. A last injection of antibodies or PBS is given 6 days after
surgery and the animals are sacrificed 15 days later. The injured
carotid artery is fixed, embedded in paraffin and sectioned. The
size of the neo-intimal plaque is measured using computer-based
image analysis.
[0087] 3. Effect of Antibodies on Uptake of Oxidized LDL in
Cultured Human Macrophages.
[0088] Uptake of oxidized LDL in arterial macrophages leading to
formation of cholesterol-loaded macrophage foam cells is one of the
most characteristic features of the atherosclerotic plaque. Several
lines of evidence suggest that inhibiting uptake of oxidized LDL in
arterial macrophages represent a possible target for treatment of
atherosclerosis. To study the effect of antibodies on macrophage
uptake of oxidized c are pre-incubated with .sup.125I-labeled human
oxidized LDL for 2 hours. Human macrophages are isolated from blood
donor buffy coats by centrifugation in Ficoll hypaque followed by
culture in presence of 10% serum for 6 days. The cells are then
incubated with medium containing antibody/oxidized LDL complexes
for 6 hours, washed and cell-associated radioactivity determined in
a gamma-counter. Addition of IEI-E3 antibodies resulted in a
five-fold increase in the binding (P=0.001) and uptake (P=0.004) of
oxidized LDL compared to FITC-8 into macrophages, but had no effect
on binding or uptake of native LDL (FIGS. 8a and 8b).
[0089] 4. Effect of antibodies on oxidized LDL-dependent
cytotoxicity. Oxidized LDL is highly cytotoxic. It is believed that
much of the inflammatory activity in atherosclerotic plaques is
explained by cell injury caused by oxidized LDL. Inhibition of
oxidized LDL cytotoxicity thus represents another possible target
for treatment of atherosclerosis. To study the effect of antibodies
on oxidized LDL cytotoxicity cultured human arterial smooth muscle
cells are exposed to 100 ng/ml of human oxidized LDL in the
presence of increasing concentrations of antibodies (0-200 ng/ml)
for 48 hours. The rate of cell injury is determined by measuring
the release of the enzyme LDH.
[0090] The experiment shown discloses an effect for a particular
antibody raised against a particular peptide, but it is evident to
the one skilled in the art that all other antibodies raised against
the peptides disclosed will behave in the same manner.
[0091] The antibodies of the present invention are used in
pharmaceutical compositions for passive immunization, whereby the
pharmaceutical compositions primarily are intended for injection,
comprising a solution, suspension, or emulsion of a single antibody
or a mixture of antibodies of the invention in a dosage to provide
a therapeutically or prophylactically active level in the body
treated. The compositions may be provided with commonly used
adjuvants to enhance absorption of the antibody or mixture of
antibodies. Other routes of administration may be the nasal route
by inhaling the antibody/antibody mixture in combination with
inhalable excipients.
[0092] Such pharmaceutical compositions may contain the active
antibody in an amount of 0.5 to 99.5% by weight, or 5 to 90% by
weight, or 10 to 90% by weight, or 25 to 80% by weight, or 40 to
90% by weight.
[0093] The daily dosage of the antibody, or a booster dosage shall
provide for a therapeutically or prophylactically active level in
the body treated to reduce or prevent signs and symptoms of
atherosclerosis by way of passive immunization. A dosage of
antibody according to the invention may be 1 g to 1 mg per kg
bodyweight, or more.
[0094] The antibody composition can be supplemented with other
drugs for treating or preventing atherosclerosis or heart-vascular
diseases, such as blood pressure lowering drugs, such as
beta-receptor blockers, calcium antagonists, diurethics, and other
antihypertensive agents.
Sequence CWU 1
1
791369DNAArtificial SequenceDescription of Artificial Sequence
Synthetic nucleotide sequence 1gaggtgcagc tgttggagtc tgggggaggc
ttggtacagc ctggggggtc cctgagactc 60tcctgtgcag cctctggatt caccttcaat
aacgcctgga tgagctgggt ccgccaggct 120ccagggaagg ggctggagtg
ggtctcatcc attagtagta gtagtagtta catatactac 180gcagactcag
tgaagggccg attcaccatc tccagagaca attccaagaa cacgctgtat
240ctgcaaatga acagcctgag agccgaggac actgccgtgt attactgtgc
gagagtcagt 300aggtactact acggaccatc tttctacttt gactcctggg
gccagggtac actggtcacc 360gtgagcagc 3692336DNAArtificial
SequenceDescription of Artificial Sequence Synthetic nucleotide
sequence 2cagtctgtgc tgactcagcc accctcagcg tctgggaccc ccgggcagag
ggtcaccatc 60tcctgctctg gaagcaggtc caacattggg aataattatg tatcctggta
tcagcagctc 120ccaggaacgg cccccaaact cctcatctat ggtaacaaca
atcggccctc aggggtccct 180gaccgattct ctggctccaa gtctggcacc
tcagcctccc tggccatcag tgggctccgg 240tccgaggatg aggctgatta
ttactgtgca gcatgggatg acagcctgaa tggtcattgg 300gtgttcggcg
gaggaaccaa gctgacggtc ctaggt 3363366DNAArtificial
SequenceDescription of Artificial Sequence Synthetic nucleotide
sequence 3gaggtgcagc tgttggagtc tgggggaggc ttggtacagc ctggggggtc
cctgagactc 60tcctgtgcgg cctctggatt caccttcagt gactactaca tgagctgggt
ccgccaggct 120cccgggaagg ggctggagtg ggtatcgggt gttagttgga
atggcagtag gacgcactat 180gcagactctg tgaagggccg attcaccatc
tccagagaca attccaagaa cacgctgtat 240ctgcaaatga acagcctgag
agccgaggac actgccgtgt attactgtgc gagagcggct 300aggtactcct
actactacta cggtatggac gtctggggcc aaggtacact ggtcaccgtg 360agcagc
3664327DNAArtificial SequenceDescription of Artificial Sequence
Synthetic nucleotide sequence 4cagtctgtgc tgactcagcc accctcagcg
tctgggaccc ccgggcagag ggtcaccatc 60tcctgttctg gaagcagctc caacatcgga
aataatgctg taaactggta tcagcagctc 120ccaggaacgg cccccaaact
cctcatctat gggaatgatc ggcggccctc aggggtccct 180gaccgattct
ctggctccaa gtctggcacc tcagcctccc tggccatcag tgggctccgg
240tccgaggatg aggctgatta ttactgtcag acctggggca ctggccgggg
ggtattcggc 300ggaggaacca agctgacggt cctaggt 3275366DNAArtificial
SequenceDescription of Artificial Sequence Synthetic nucleotide
sequence 5gaggtgcagc tgttggagtc tgggggaggc ttggtacagc ctggggggtc
cctgagactc 60tcctgtgcag cctctggatt cacctttagt agctattgga tgagctgggt
ccgccaggct 120ccagggaagg ggctggagtg ggtctcaagt atcagtggta
gtggtcgtag gacatactac 180gcagactccg tgcagggccg gttcaccatc
tccagagaca attccaagaa cacgctgtat 240ctgcaaatga acagcctgag
agccgaggac actgccgtgt attactgtgc gagattggtc 300tcctatggtt
cggggagttt cggttttgac tactggggcc aaggtacact ggtcaccgtg 360agcagc
3666333DNAArtificial SequenceDescription of Artificial Sequence
Synthetic nucleotide sequence 6cagtctgtgc tgactcagcc accctcagcg
tctgggaccc ccgggcagag ggtcaccatc 60tcttgttctg gaagcagctc caatatcgga
agtaattatg tatcctggta tcagcagctc 120ccaggaacgg cccccaaact
cctcatctat ggtaactaca atcggccctc aggggtccct 180gaccgattct
ctggctccaa gtctggcacc tcagcctccc tggccatcag tgggctccgg
240tccgaggatg aggctgatta ttactgtgca gcatgggatg acagcctgag
tggttgggtg 300ttcggcggag gaaccaagct gacggtccta ggt
3337378DNAArtificial SequenceDescription of Artificial Sequence
Synthetic nucleotide sequence 7gaggtgcagc tgttggagtc tgggggaggc
ttggtacagc ctggggggtc cctgagactc 60tcctgtgcag cctctggatt caccttcagt
aacgcctgga tgagctgggt ccgccaggtt 120ccagggaagg ggctggagtg
ggtctcaact cttggtggta gtggtggtgg tagcacatac 180tacgcagact
ccgtgaaggg ccggttcacc atctccagag acaattccaa gaacacgctg
240tatctgcaaa tgaacagcct gagagccgag gacactgccg tgtattactg
tgcgaagtta 300ggggggcgat cccgatatgg gcggtggccc cgccaatttg
actactgggg ccaaggtaca 360ctggtcaccg tgagcagc 3788333DNAArtificial
SequenceDescription of Artificial Sequence Synthetic nucleotide
sequence 8cagtctgtgc tgactcagcc accctcagcg tctgggaccc ccgggcagag
ggtcaccatc 60tcctgctctg gaagcagctc caacattgga aataactatg tatcctggta
tcagcagctc 120ccaggaacgg cccccaaact cctcatctat agtaataatc
agcggccctc aggggtccct 180gaccgattct ctggctccaa gtctggcacc
tcagcctccc tggccatcag tgggctccgg 240tccgaggatg aggctgatta
ttactgtgca gcatgggatg acagcctgag tcattggctg 300ttcggcggag
gaaccaagct gacggtccta ggt 3339372DNAArtificial SequenceDescription
of Artificial Sequence Synthetic nucleotide sequence 9gaggtgcagc
tgttggagtc tgggggaggc ttggtacagc ctggggggtc cctgagactc 60tcctgtgcag
cctctggatt caccttcagt gactactaca tgagctggat ccgccaggct
120ccagggaagg ggctggagtg ggtctcaagt atcagtggcc gtgggggtag
ttcctactac 180gcagactccg tgaggggccg gttcaccatc tccagagaca
attccaagaa cacgctgtat 240ctgcaaatga acagcctgag agccgaggac
actgccgtgt attactgtgc gagactttcc 300tacagctatg gttacgaggg
ggcctactac tttgactact ggggccaggg tacactggtc 360accgtgagca gc
37210333DNAArtificial SequenceDescription of Artificial Sequence
Synthetic nucleotide sequence 10cagtctgtgc tgactcagcc accctcagcg
tctgggaccc ccgggcagag ggtcaccatc 60tcctgctctg gaagcagctc caacattggg
aataattatg tatcctggta tcagcagctc 120ccaggaacgg cccccaaact
cctcatctat aggaataatc agcggccctc aggggtccct 180gaccgattct
ctggctccaa gtctggcacc ttagcctccc tggccatcag tgggctccgg
240tccgaggatg aggctgatta ttactgtgca acctgggatg acagcctgaa
tggttgggtg 300ttcggcggag gaaccaagct gacggtccta ggt
33311363DNAArtificial SequenceDescription of Artificial Sequence
Synthetic nucleotide sequence 11gaggtgcagc tgttggagtc tgggggaggc
ttggtacagc ctggggggtc cctgagactc 60tcctgtgcag cctctggatt cacctttagc
agctatgcca tgagctgggt ccgccaggct 120ccagggaagg ggctggagtg
ggtctcatcc attagtagta gtggtcgttt catttactac 180gcagactcaa
tgaagggccg cttcaccatc tccagagaca attccaagaa cacgctgtat
240ctgcaaatga acagcctgag agccgaggac actgccgtgt attactgtac
gaggctccgg 300agagggagct acttctgggc ttttgatatc tggggccaag
gtacactggt caccgtgagc 360agc 36312333DNAArtificial
SequenceDescription of Artificial Sequence Synthetic nucleotide
sequence 12cagtctgtgc tgactcagcc accctcagcg tctgggaccc ccgggcagag
ggtcaccatc 60tcctgttctg gaagcagctc caacattggc ggtgagtctg tatcctggta
tcagcagctc 120ccaggaacgg cccccaaact cctcatctat agtaataatc
agcggccctc aggggtccct 180gaccgattct ctggctccaa gtctggcacc
tcagcctccc tggccatcag tgggctccgg 240tccgaggatg aggctgatta
ttactgtgca gcatgggatg acagcctgaa tggttgggtg 300ttcggcggag
gaaccaagct gacggtccta ggt 3331330DNAArtificial SequenceDescription
of Artificial Sequence Synthetic primer 13ggtgtgcatt ccgaggtgca
gctgttggag 301433DNAArtificial SequenceDescription of Artificial
Sequence Synthetic primer 14gacgtacgac tcacctgagc tcacggtgac cag
331530DNAArtificial SequenceDescription of Artificial Sequence
Synthetic primer 15ggtgtgcatt cccagtctgt gctgactcag
301634DNAArtificial SequenceDescription of Artificial Sequence
Synthetic primer 16gacgtacgtt ctactcacct aggaccgtca gctt
341718DNAArtificial SequenceDescription of Artificial Sequence
Synthetic primer 17atgggtgaca atgacatc 181817DNAArtificial
SequenceDescription of Artificial Sequence Synthetic primer
18aagcttgcta gcgtacg 1719369DNAArtificial SequenceDescription of
Artificial Sequence Synthetic nucleotide sequence 19gaggtgcagc
tgttggagtc tgggggaggc ttggtacagc ctggggggtc cctgagactc 60tcctgtgcag
cctctggatt cacctttaga acgtattgga tgacctgggt ccgccaggct
120ccagggaagg ggctggagtg ggtctcatct attagcagta gcagtaatta
catattctac 180gcagactcag tgaagggccg attcaccatc tccagagaca
attccaagaa cacgctgtat 240ctgcaaatga acagcctgag agccgaggac
actgccgtgt attactgtgc gagactcaga 300cggagcagct ggtacggggg
gtactggttc gacccctggg gccaaggtac actggtcacc 360gtgagctca
36920336DNAArtificial SequenceDescription of Artificial Sequence
Synthetic nucleotide sequence 20cagtctgtgc tgactcagcc accctcagcg
tctgggaccc ccgggcagag ggtcaccatc 60tcctgctctg gaagcagctc caacattggg
aataattatg tatcctggta tcagcagctc 120ccaggaacgg cccccaaact
cctcatctat aggaataatc agcggccctc aggggtccct 180gaccgattct
ctggctccaa gtctggcacc tcagcctccc tggccatcag tgggctccgg
240tccgaggatg aggctgatta ttactgtgca gcatgggatg acagcctgaa
tggtcattgg 300gtgttcggcg gaggaaccaa gctgacggtc ctaggt
33621369DNAArtificial SequenceDescription of Artificial Sequence
Synthetic nucleotide sequence 21gaggtgcagc tgttggagtc tgggggaggc
ttggtacagc ctggggggtc cctgagactc 60tcctgtgcag cctctggatt caccttcagt
agcaactaca tgagctgggt ccgccaggct 120ccagggaagg ggctggagtg
ggtctcatcc attagtagta gtagtagtta catatactac 180gcagactcag
tgaagggccg attcaccatc tccagagaca attccaagaa cacgctgtat
240ctgcaaatga acagcctgag agccgaggac actgccgtgt attactgtgc
gagagtaggc 300cggtataact ggaagacggg gcatgctttt gatatctggg
gccagggtac actggtcacc 360gtgagctca 36922333DNAArtificial
SequenceDescription of Artificial Sequence Synthetic nucleotide
sequence 22cagtctgtgc tgactcagcc accctcagcg tctgggaccc ccgggcagag
ggtcaccatc 60tcctgctctg gaaggaccta caacattgga aataattatg tatcgtggta
tcagcagctc 120ccaggaacgg cccccaaact cctcatctat ggtaacatca
atcggccctc aggggtccct 180gaccgattct ctggctccaa gtctggcacc
tcagcctccc tggccatcag tgggctccgg 240tccgaggatg aggctgatta
ttactgtgca gcatgggatg tcaggctgaa tggttgggtg 300ttcggcggag
gaaccaagct gacggtccta ggt 33323381DNAArtificial SequenceDescription
of Artificial Sequence Synthetic nucleotide sequence 23gaggtgcagc
tgttggagtc tgggggaggc ttggtacagc ctggggggtc cctgagactc 60tcctgtgcag
cctctggatt caccttccgt gactactacg tgagctggat ccgccaggct
120ccagggaagg ggctggagtg ggtctcaagt attagtggta gtgggggtag
gacatactac 180gcagactccg tggagggccg gttcaccatc tccagagaca
attccaagaa cacgctgtat 240ctgcaaatga acagcctgag agccgaggac
actgccatgt attactgtgc cagagtatcc 300gcccttcgga gacccatgac
tacagtaact acttactggt tcgacccctg gggccaaggt 360acactggtca
ccgtgagctc a 38124333DNAArtificial SequenceDescription of
Artificial Sequence Synthetic nucleotide sequence 24cagtctgtgc
tgactcagcc accctcagcg tctgggaccc ccgggcagag ggtcaccatc 60tcctgctctg
gaaggagctc caacattggg aatagttatg tctcctggta tcagcagctc
120ccaggaacgg cccccaaact cctcatctat aggaataatc agcggccctc
aggggtccct 180gaccgattct ctggctccaa gtctggcacc tcagcctccc
tggccatcag tgggctccgg 240tccgaggatg aggctgatta ttactgtgca
ggatgggatg acaccctgcg tgcttgggtg 300ttcggcggag gaaccaagct
gacggtccta ggt 33325360DNAArtificial SequenceDescription of
Artificial Sequence Synthetic nucleotide sequence 25gaggtgcagc
tgttggagtc tgggggaggc ttggtacagc ctggggggtc cctgagactc 60tcctgtgcag
cctctggatt caccttcagt aacgcctgga tgagctgggt ccgccaggct
120ccagggaagg ggctggagtg ggtctccgct attagtggta gtggtaacac
atactatgca 180gactccgtga agggccggtt caccatctcc agagacaatt
ccaagaacac gctgtatctg 240caaatgaaca gcctgagagc cgaggacact
gccgtgtatt actgtgcgag agcctcccac 300cgtatattag gttatgcttt
tgatatctgg ggccagggta cactggtcac cgtgagctca 36026328DNAArtificial
SequenceDescription of Artificial Sequence Synthetic nucleotide
sequence 26cagtctgtgc tgactcagcc accctcagcg tctgggaccc ccgggcagag
ggtcaccatc 60tcttgttctg gaagccgctc caacatcggg agaaatgctg ttagttggta
tcagcagctc 120ccaggaacgg cccccaaact cctcatctat gctaacagca
atcggccctc aggggtccct 180gaccgattct ctggctccaa gtctggcacc
tcagcctccc tggccatcag tgggctccgg 240tccgaggatg aggctgatta
ttactgtgca gcatgggatg gcagcctgaa tggttgggtg 300ttcggcggag
gaaccaagct gacggtcc 32827363DNAArtificial SequenceDescription of
Artificial Sequence Synthetic nucleotide sequence 27gaggtgcagc
tgttggagtc tgggggaggc ttggtacagc ctggggggtc cctgagactc 60tcctgtgcag
cctctggatt caccttcagt aacgcctgga tgagctgggt ccgccaggct
120ccagggaagg ggctggagtg ggtctcaagt attagtgttg gtggacatag
gacatattat 180gcagattccg tgaagggccg gtccaccatc tccagagaca
attccaagaa cacgctgtat 240ctgcaaatga acagcctgag agccgaggac
actgccgtgt attactgtgc acggatacgg 300gtgggtccgt ccggcggggc
ctttgactac tggggccagg gtacactggt caccgtgagc 360tca
36328333DNAArtificial SequenceDescription of Artificial Sequence
Synthetic nucleotide sequence 28cagtctgtgc tgactcagcc accctcagcg
tctgggaccc ccgggcagag ggtcaccatc 60tcctgctctg gaagcaacac caacattggg
aagaactatg tatcttggta tcagcagctc 120ccaggaacgg cccccaaact
cctcatctat gctaatagca atcggccctc aggggtccct 180gaccgattct
ctggctccaa gtctggcacc tcagcctccc tggccatcag tgggctccgg
240tccgaggatg aggctgatta ttactgtgcg tcatgggatg ccagcctgaa
tggttgggta 300ttcggcggag gaaccaagct gacggtccta ggt
33329378DNAArtificial SequenceDescription of Artificial Sequence
Synthetic nucleotide sequence 29gaggtgcagc tgttggagtc tgggggaggc
ttggtacagc ctggggggtc cctgagactc 60tcctgtgcag cctctggatt caccttcagt
aacgcctgga tgagctgggt ccgccaggct 120ccagggaagg ggctggagtg
ggtctcatcc attagtagta gtagtagtta catatactac 180gcagactcag
tgaagggccg atccaccatc tccagagaca attccaagaa cacgctgtat
240ctgcaaatga acagcctgag agccgaggac actgccgtgt attactgtgc
gaggctcaca 300aatattttga ctggttatta tacctcagga tatgcttttg
atatctgggg ccaaggtaca 360ctggtcaccg tgagctca 37830333DNAArtificial
SequenceDescription of Artificial Sequence Synthetic nucleotide
sequence 30cagtctgtgc tgactcagcc accctcagcg tctgggaccc ccgggcagag
ggtcaccatc 60tcctgctctg gaagcacctc caacattggg aagaattatg tatcctggta
tcagcagctc 120ccaggaacgg cccccaaact cctcatctat ggtaacagca
atcggccctc aggggtccct 180gaccgattct ctggctccaa gtctggcacc
tcagcctccc tggccatcag tgggctccgg 240tccgaggatg aggctgatta
ttactgtgca gcatgggatg ccagcctcag tggttgggtg 300ttcggcggag
gaaccaagct gacggtccta ggt 33331363DNAArtificial SequenceDescription
of Artificial Sequence Synthetic nucleotide sequence 31gaggtgcagc
tgttggagtc tgggggaggc ttggtacagc ctggggggtc cctgagactc 60tcctgtgcag
cctctggatt caccttcagt agttcttgga tgagttgggt ccgccaggct
120ccagggaagg ggctggagtg ggtctcatcc attagtagta gtagtagtta
catatactac 180gcagactcag tgaagggccg attcaccatc tccagagaca
attccaagaa cacgctgtat 240ctgcaaatga acagcctgag agccgaggac
actgccgtgt attactgtgc gagagtaggg 300aactacggtt tctaccacta
catggacgtc tggggccaag gtacactggt caccgtgagc 360tca
36332333DNAArtificial SequenceDescription of Artificial Sequence
Synthetic nucleotide sequence 32cagtctgtgc tgactcagcc accctcagcg
tctgggaccc ccgggcagag ggtcaccatc 60tcttgttctg gaggcagctc aaacatcgga
aaaagaggtg taaattggta tcagcagctc 120ccaggaacgg cccccaaact
cctcatctat ggtaacagaa atcggccctc aggggtccct 180gaccgattct
ctggctccaa gtctggcacc tcagcctccc tggccatcag tgggctccgg
240tccgaggatg aggctgatta ttactgtgct acatgggatt acagcctcaa
tgcttgggtg 300ttcggcggag gaaccaagct gacggtccta ggt
33333366DNAArtificial SequenceDescription of Artificial Sequence
Synthetic nucleotide sequence 33gaggtgcagc tgttggagtc tgggggaggc
ttggtacagc ctggggggtc cctgagactc 60tcctgtgcag cctctggatt cacctttagt
agctattgga tgagctgggt ccgccaggct 120ccagggaagg ggctggagtg
ggtctcatcc attagtagta gtagtagtta catatactac 180gcagactcag
tgaagggccg attcaccatc tccagagaca attccaagaa cacgctgtat
240ctgcaaatga acagcctgag agccgaggac actgccgtgt attactgtgc
gagaattaaa 300cggttacgat tcggctggac cccttttgac tactggggcc
agggtacact ggtcaccgtg 360agctca 36634333DNAArtificial
SequenceDescription of Artificial Sequence Synthetic nucleotide
sequence 34cagtctgttc tgactcagcc accctcagcg tctgggaccc ccgggcagag
ggtcaccatc 60tcctgttctg gaagcagctc caacatcgga aataatggtg taaactggta
tcagcagctc 120ccaggaacgg cccccaaact cctcatctat ggtaacaaca
atcggccctc aggggtccct 180gaccgattct ctggctccaa gtctggcacc
tcagcctccc tggccatcag tgggctccgg 240tccgaggatg aggctgatta
ttactgtgca gcatgggatg acagcctgcg tggttggctg 300ttcggcggag
gaaccaagct gacggtccta ggt 33335369DNAArtificial SequenceDescription
of Artificial Sequence Synthetic nucleotide sequence 35gaggtgcagc
tgttggagtc tgggggaggc ttggtacagc ctggggggtc cctgagactc 60tcctgtgcag
cctctggatt caccttcagt aacgcctgga tgagctgggt ccgccaggct
120ccagggaagg ggctggagtg ggtctcatcc attagtagta gtagtagtta
catatactac 180gcagactcag tgaagggccg attcaccatc tccagagaca
attccaagaa cacgctgtat 240ctgcaaatga acagcctgag agccgaggac
actgccgtgt attactgtgc gagagtcaat 300agcaaaaagt ggtatgaggg
ctacttcttt gactactggg gccagggtac actggtcacc 360gtgagctca
36936333DNAArtificial SequenceDescription of Artificial Sequence
Synthetic nucleotide sequence 36cagtctgtgc tgactcagcc accctcagcg
tctgggaccc ccgggcagag ggtcaccatc 60tcctgctctg gaagcagctc caacattggg
aataattatg tatcctggta tcagcagctc 120ccaggaacgg cccccaaact
cctcatctat ggtaacagca atcggccctc aggggtccct 180gaccgattct
ctggctccaa gtctggcacc tcagcctccc tggccatcag tgggctccgg
240tccgaggatg aggctgatta
ttactgtgca gcatgggatg acagtctgag tggttgggtg 300ttcggcggag
gaaccaagct gacggtccta ggt 33337375DNAArtificial SequenceDescription
of Artificial Sequence Synthetic nucleotide sequence 37gaggtgcagc
tgttggagtc tgggggaggc ttggtacagc ctggggggtc cctgagactc 60tcctgtgcag
cctctggatt caccttcagt aacgcctgga tgagctgggt ccgccaggct
120ccagggaagg ggctggagtg ggtctcatcc attagtacta gtagtaatta
catatactac 180gcagactcag tgaagggccg gttcaccatc tccagagaca
attccaagaa cacgctgtat 240ctgcaaatga acagcctgag agccgaggac
actgccgtgt attactgtgc gagagtcaag 300aagtatagca gtggctggta
ctcgaattat gcttttgata tctggggcca aggtacactg 360gtcaccgtga gctca
37538333DNAArtificial SequenceDescription of Artificial Sequence
Synthetic nucleotide sequence 38cagtctgtgc tgactcagcc accctcagcg
tctgggaccc ccgggcagag ggtcaccatc 60tcctgctctg gaagcagctc cagcattggg
aataattttg tatcctggta tcagcagctc 120ccaggaacgg cccccaaact
cctcatctat gacaataata agcgaccctc aggggtccct 180gaccgattct
ctggctccaa gtctggcacc tcagcctccc tggccatcag tgggctccgg
240tccgaggatg aggctgatta ttactgtgca gcatgggatg acagcctgaa
tggttgggtg 300ttcggcggag gaaccaagct gacggtccta ggt
3333920PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 39Phe Leu Asp Thr Val Tyr Gly Asn Cys Ser Thr His
Phe Thr Val Lys 1 5 10 15Thr Arg Lys Gly 204020PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 40Pro
Gln Cys Ser Thr His Ile Leu Gln Trp Leu Lys Arg Val His Ala 1 5 10
15Asn Pro Leu Leu 204120PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 41Val Ile Ser Ile Pro Arg Leu
Gln Ala Glu Ala Arg Ser Glu Ile Leu 1 5 10 15Ala His Trp Ser
204220PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 42Lys Leu Val Lys Glu Ala Leu Lys Glu Ser Gln Leu
Pro Thr Val Met 1 5 10 15Asp Phe Arg Lys 204320PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 43Leu
Lys Phe Val Thr Gln Ala Glu Gly Ala Lys Gln Thr Glu Ala Thr 1 5 10
15Met Thr Phe Lys 204420PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 44Asp Gly Ser Leu Arg His Lys
Phe Leu Asp Ser Asn Ile Lys Phe Ser 1 5 10 15His Val Glu Lys
204520PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 45Lys Gly Thr Tyr Gly Leu Ser Cys Gln Arg Asp Pro
Asn Thr Gly Arg 1 5 10 15Leu Asn Gly Glu 204620PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 46Arg
Leu Asn Gly Glu Ser Asn Leu Arg Phe Asn Ser Ser Tyr Leu Gln 1 5 10
15Gly Thr Asn Gln 204720PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 47Ser Leu Thr Ser Thr Ser Asp
Leu Gln Ser Gly Ile Ile Lys Asn Thr 1 5 10 15Ala Ser Leu Lys
204820PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 48Thr Ala Ser Leu Lys Tyr Glu Asn Tyr Glu Leu Thr
Leu Lys Ser Asp 1 5 10 15Thr Asn Gly Lys 204920PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 49Asp
Met Thr Phe Ser Lys Gln Asn Ala Leu Leu Arg Ser Glu Tyr Gln 1 5 10
15Ala Asp Tyr Glu 205020PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 50Met Lys Val Lys Ile Ile Arg
Thr Ile Asp Gln Met Gln Asn Ser Glu 1 5 10 15Leu Gln Trp Pro
205120PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 51Ile Ala Leu Asp Asp Ala Lys Ile Asn Phe Asn Glu
Lys Leu Ser Gln 1 5 10 15Leu Gln Thr Tyr 205220PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 52Lys
Thr Thr Lys Gln Ser Phe Asp Leu Ser Val Lys Ala Gln Tyr Lys 1 5 10
15Lys Asn Lys His 205320PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 53Glu Glu Glu Met Leu Glu Asn
Val Ser Leu Val Cys Pro Lys Asp Ala 1 5 10 15Thr Arg Phe Lys
205420PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 54Gly Ser Thr Ser His His Leu Val Ser Arg Lys Ser
Ile Ser Ala Ala 1 5 10 15Leu Glu His Lys 205520PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 55Ile
Glu Asn Ile Asp Phe Asn Lys Ser Gly Ser Ser Thr Ala Ser Trp 1 5 10
15Ile Gln Asn Val 205620PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 56Ile Arg Glu Val Thr Gln Arg
Leu Asn Gly Glu Ile Gln Ala Leu Glu 1 5 10 15Leu Pro Gln Lys
205720PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 57Glu Val Asp Val Leu Thr Lys Tyr Ser Gln Pro Glu
Asp Ser Leu Ile 1 5 10 15Pro Phe Phe Glu 205820PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 58His
Thr Phe Leu Ile Tyr Ile Thr Glu Leu Leu Lys Lys Leu Gln Ser 1 5 10
15Thr Thr Val Met 205920PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 59Leu Leu Asp Ile Ala Asn Tyr
Leu Met Glu Gln Ile Gln Asp Asp Cys 1 5 10 15Thr Gly Asp Glu
206020PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 60Cys Thr Gly Asp Glu Asp Tyr Thr Tyr Lys Ile Lys
Arg Val Ile Gly 1 5 10 15Asn Met Gly Gln 206120PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 61Gly
Asn Met Gly Gln Thr Met Glu Gln Leu Thr Pro Glu Leu Lys Ser 1 5 10
15Ser Ile Leu Lys 206220PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 62Ser Ser Ile Leu Lys Cys Val
Gln Ser Thr Lys Pro Ser Leu Met Ile 1 5 10 15Gln Lys Ala Ala
206320PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 63Ile Gln Lys Ala Ala Ile Gln Ala Leu Arg Lys Met
Glu Pro Lys Asp 1 5 10 15Lys Asp Gln Glu 206420PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 64Arg
Leu Asn Gly Glu Ser Asn Leu Arg Phe Asn Ser Ser Tyr Leu Gln 1 5 10
15Gly Thr Asn Gln 206520PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 65Ser Leu Asn Ser His Gly Leu
Glu Leu Asn Ala Asp Ile Leu Gly Thr 1 5 10 15Asp Lys Ile Asn
206620PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 66Trp Ile Gln Asn Val Asp Thr Lys Tyr Gln Ile Arg
Ile Gln Ile Gln 1 5 10 15Glu Lys Leu Gln 206720PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 67Thr
Tyr Ile Ser Asp Trp Trp Thr Leu Ala Ala Lys Asn Leu Thr Asp 1 5 10
15Phe Ala Glu Gln 206820PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 68Glu Ala Thr Leu Gln Arg Ile
Tyr Ser Leu Trp Glu His Ser Thr Lys 1 5 10 15Asn His Leu Gln
206920PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 69Ala Leu Leu Val Pro Pro Glu Thr Glu Glu Ala Lys
Gln Val Leu Phe 1 5 10 15Leu Asp Thr Val 207020PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 70Ile
Glu Ile Gly Leu Glu Gly Lys Gly Phe Glu Pro Thr Leu Glu Ala 1 5 10
15Leu Phe Gly Lys 207120PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 71Ser Gly Ala Ser Met Lys Leu
Thr Thr Asn Gly Arg Phe Arg Glu His 1 5 10 15Asn Ala Lys Phe
207220PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 72Asn Leu Ile Gly Asp Phe Glu Val Ala Glu Lys Ile
Asn Ala Phe Arg 1 5 10 15Ala Lys Val His 207320PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 73Gly
His Ser Val Leu Thr Ala Lys Gly Met Ala Leu Phe Gly Glu Gly 1 5 10
15Lys Ala Glu Phe 207420PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 74Phe Lys Ser Ser Val Ile Thr
Leu Asn Thr Asn Ala Glu Leu Phe Asn 1 5 10 15Gln Ser Asp Ile
207520PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 75Phe Pro Asp Leu Gly Gln Glu Val Ala Leu Asn Ala
Asn Thr Lys Asn 1 5 10 15Gln Lys Ile Arg 207623DNAArtificial
SequenceDescription of Artificial Sequence Synthetic primer
76cccagtcacg acgttgtaaa acg 237725DNAArtificial SequenceDescription
of Artificial Sequence Synthetic primer 77gaaacagcta tgaaatacct
attgc 257817DNAArtificial SequenceDescription of Artificial
Sequence Synthetic primer 78caggaaacag ctatgac 177921DNAArtificial
SequenceDescription of Artificial Sequence Synthetic primer
79agacccaagc tagcttggta c 21
* * * * *